The spectrum of the phenotypes in the C9ORF72 expansion carriers by Solje, Eino
D
IS
S
E
R
T
A
T
IO
N
S
  |  E
IN
O
 S
O
L
JE
  |   T
H
E
 S
P
E
C
T
R
U
M
 O
F
 T
H
E
 P
H
E
N
O
T
Y
P
E
S
 IN
 T
H
E
 C
9
O
R
F
72 E
X
P
A
N
S
IO
N
 ...  |  N
o
 334 
uef.fi
PUBLICATIONS OF 
THE UNIVERSITY OF EASTERN FINLAND
Dissertations in Health Sciences
ISBN 978-952-61-2053-9
ISSN 1798-5706
Dissertations in Health Sciences
PUBLICATIONS OF 
THE UNIVERSITY OF EASTERN FINLAND
EINO SOLJE
THE SPECTRUM OF THE PHENOTYPES IN 
THE C9ORF72 EXPANSION CARRIERS
Insights at the Interface between Neurology and Psychiatry
 
Behavioural variant frontotemporal 
dementia (bvFTD) is a less well-known 
neurodegenerative disease. The C9ORF72 
expansion is the most common genetic 
etiology for bvFTD in Finland. There is a 
broad phenotype in the C9ORF72 expansion 
associated bvFTD; psychiatric symptoms 
are pronounced. This thesis focuses on 
characterizing the clinical phenotype and 
diagnostics of the C9ORF72 expansion carriers; 
this will be an important issue when new 
targeted pharmaceuticals become available.
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ABSTRACT:  
 
Frontotemporal lobar degeneration (FTLD) is the second most common etiology responsible for early 
onset dementia. The syndrome is clinically divided into behavioural variant frontotemporal dementia 
(bvFTD) and primary progressive aphasias (PPA). There can be a delay of several years before 
physicians can make an accurate bvFTD diagnosis, because the early signs of the disease are rather 
common psychiatric symptoms rather than characteristic memory problems and this problem is 
accentuated by the lack of diagnostic biomarkers. A considerable number of FTLD cases are familial 
and the C9ORF72 repeat expansion has been identified as the most common causative mutation for 
the FTLD in Finland. The phenotypes associated to the C9ORF72 expansion are very variable and so 
far, the exact phenotype has not been accurately described according to the new diagnostic criteria 
for bvFTD.  
The aim of this study was evaluate the phenotypes associated with the C9ORF72 expansion. The 
clinical significance of the mutation was analyzed in three distinct cohorts: 1) in patients suffering 
from the C9ORF72 expansion associated bvFTD (n=36), 2) in patients with schizophrenia and other 
psychoses from the Northern Finland Birth Cohort 1966 (NFBC 1966) (n=130) and 3) in the victims of 
suicide in Northern Finland (n=109). The sensitivity of the latest diagnostic criteria for bvFTD 
(Rascovsky criteria), the disease course of bvFTD and psychiatric manifestations among the C9ORF72 
expansion carriers were evaluated. The prevalence of the C9ORF72 expansion and its intermediate 
length repeats were analyzed in the psychiatric cohorts. In addition, the effect of the C9ORF72 
expansion on the phenotype of Nasu-Hakola disease was assessed.  
The sensitivity of the latest clinical diagnostic criteria was 75% for possible and 64% for probable 
bvFTD among the patients with the C9ORF72 expansion. However, there was extensive clinical 
variability of the phenotypes between patients. The carriers of the C9ORF72 expansion display many 
psychiatric (mood and psychotic) symptoms and 60% of patients have had a psychiatric consultation 
before or at the time of the bvFTD diagnosis. According the criteria, brain imaging exhibits rather 
high sensitivity (86%). However, normal brain imaging was detected in 14% of patients. The full 
length pathological C9ORF72 expansion was not detected in any of the schizophrenic patients or 
suicide victims. In addition, the phenotype of Nasu-Hakola disease was not modified by the 
pathological C9ORF72 expansion.  
In conclusion, patients with the C9ORF72 expansion experience psychiatric symptoms years before 
there is any suspicion of bvFTD. This dementing disease should be suspected in subjects with severe 
psychiatric symptoms appearing in middle age or slightly later despite normal brain imaging 
findings.  
 
 
National Library of Medicine Classification: QZ 50, WM 220, WL 358.5, WL 141 
Medical Subject Headings: Neurodegenerative Diseases; Dementia; Frontotemporal Lobar Degeneration; 
Frontotemporal Dementia; Genetics; Mutation; DNA Repeat Expansion; Phenotype; Early Diagnosis; 
Cognition; Neuroimaging; Behavioral Symptoms; Impulsive Behavior; Inhibition (Psychology); Diagnosis, 
Differential; Schizophrenia; Suicide 
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TIIVISTELMÄ:  
 
Otsa-ohimolohkorappeumat ovat toiseksi yleisin syy työikäisenä alkavaan etenevään 
muistisairauteen. Otsa-ohimolohkorappeumat jaotellaan kliinisten oirekuvien perusteella 
käytösoireiseen otsalohkodementiaan sekä kielellisin oirein ilmenevään etenevään afasiaan. Koska 
otsalohkodementian oireet ovat alkuun pääasiassa neuropsykiatrisia ja taudille spesifisiä 
biomarkkereita ei ole käytettävissä, niin epäily muistisairaudesta herää usein myöhäisessä vaiheessa 
ja diagnostiikka viivästyy.  Merkittävä osa otsa-ohimolohkorappeumista on perinnöllisiä ja viime 
vuosina C9ORF72-toistojaksomutaation on osoitettu olevan syynä valtaosaan suomalaisista 
perinnöllisistä tautitapauksista. Mutaatioon liittyvät oirekuvat on kuvattu hyvin vaihteleviksi ja 
mutaation ilmiasu on otsalohkodementia diagnostisin kriteerein vielä kuvaamatta. 
Tässä tutkimuksessa selvitettiin C9ORF72-toistojaksomutaatioon liittyviä kliinisiä ilmentymiä. 
Mutaation aiheuttamaa oirekuvaa ja sen merkitystä on tutkittu kolmessa eri kohortissa 1) C9ORF72-
mutaatiota kantavien otsalohkodementia diagnoosin saaneiden potilaiden kohortissa (n=36), 2) 
vuonna 1966 syntyneiden pohjoissuomalaisten syntymäkohortissa (NFBC1966) skitsofreniaa ja muita 
psykooseja sairastavien osajoukossa (n=130) sekä 3) pohjoissuomalaisessa itsemurha-aineistossa 
(n=109). Ensimmäisessä kohortissa tutkittiin uusimpien otsalohkodementian diagnostisten kriteerien 
(ns. Rascovskyn kriteerit) herkkyyttä, sairaudenkulkua ja sairauden psykiatrisia ilmentymiä 
C9ORF72-mutaatiota kantavien potilaiden joukossa. Kahdessa muussa kohortissa selvitettiin 
C9ORF72-mutaation ja sen välimuotoisten pidentymien esiintyvyyttä psykiatrisessa aineistossa. 
Lisäksi tutkimuksessa selvitettiin C9ORF72-mutaation vaikutusta Nasu-Hakolan taudin kliiniseen 
oirekuvaan.  
Uusimpien kliinisten kriteerien herkkyys mahdolliselle otsalohkodementian diagnoosille oli 75 % 
ja todennäköiselle diagnoosille 64 % C9ORF72-mutaatiota kantavilla potilailla. Diagnostisten 
kriteerien kuvaamassa oirekirjossa oli merkittävää vaihtelua eri potilaiden välillä. Potilailla todettiin 
runsaasti psykiatrisia oireita, joista suurin osa oli psykoottisuutta tai mielialahäiriöitä. Lisäksi 60 % 
potilaista oli ollut psykiatrisessa hoidossa ennen otsalohkodementian diagnoosin asettamista. 
Kriteeristön mukaisilla aivojen kuvantamistutkimuksilla oli suhteellisen hyvä herkkyys tunnistaa 
otsalohkodementiaa sairastavia potilaita (86 %), mutta noin seitsemäsosalla potilaista 
kuvantamistutkimukset olivat normaaleja. Patogeenistä mutaatiota ei todettu ennen keski-ikää 
puhkeavaa skitsofreniaa sairastavien eikä itsemurhan tehneiden aineistossa, eikä mutaatio 
vaikuttanut Nasu-Hakolan taudissa sairauden kulkuun.  
Yhteenvetona voidaan todeta, että C9ORF72–toistojaksomutaation aiheuttamassa 
otsalohkodementiassa ensioireina ovat monimuotoiset psyykkiset häiriöt, jotka alkavat keski-iässä 
tai sen jälkeen. Keski-iässä alkavien vakavien psyykkisten oireiden taustalla tulisi epäillä 
otsalohkodementiaa, vaikka aivojen kuvantamistutkimuksissa ei havaittaisi poikkeavia löydöksiä.  
 
Luokitus: QZ 50, WM 220, WL 358.5, WL 141 
Yleinen suomalainen asiasanasto: muistisairaudet; dementia; otsa-ohimolohkorappeumat; perinnöllisyys; 
geenit; genetiikka; genotyyppi; geenitutkimus; mutaatiot; fenotyyppi; diagnoosi; diagnostiikka; kognitio; 
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 1 Introduction   
Frontotemporal lobar degeneration (FTLD) is the second most common cause for early onset 
degenerative brain disease (Ratnavalli et al. 2002); it accounts for approximately 10 % of all 
progressive memory diseases (Cooper-Knock, Shaw & Kirby 2014). Because the age of onset 
is substantially earlier than in other progressive memory diseases, the significance of FTLD 
is relatively more important among the working-aged population (Ratnavalli et al. 2002).  
FTLD is divided clinically into two major subtypes: 1) behavioural variant frontotemporal 
dementia (bvFTD) and 2) primary progressive aphasias (PPA) (Neary et al. 1998). BvFTD is 
a syndrome that leads to changes in both personality and behaviour. These patients may be 
impulsive or inflexible, even apathetic. Indiscreet behaviour and disinhibition occur and as 
social skills deteriorate personal relationships may be harmed (Neary, Snowden & Mann 
2005, Rascovsky et al. 2011, Piguet et al. 2011). Executive functions required for cognition are 
impaired quite soon after the initial symptoms, but visuospatial skills are preserved and this 
is combined with a relative sparing of episodic memory during the early course of the disease 
(Rascovsky et al. 2011). There is a substantial overlap in the clinical symptoms between 
bvFTD and many psychiatric disorders, especially with mood and psychotic disturbances 
(Rascovsky et al. 2011, Snowden et al. 2015).  
Autosomal dominant mutations explain 10-20 percentage of all bvFTD cases (Sieben et al. 
2012). The hexanucleotide repeat expansion in chromosome 9 (C9ORF72) has been detected 
in the majority of the familial bvFTD cases globally, but the prevalence in Finland is one of 
the highest, being present in at least half of the familial cases (Renton et al. 2011, Majounie et 
al. 2012b, DeJesus-Hernandez et al. 2011). On the other hand, other genetic causes are 
extremely rare in Finland (Kruger et al. 2009, Kaivorinne et al. 2008).  
The diagnosis of bvFTD is based on patient and caregiver interviews, neurological 
assessment, neuropsychological test batteries and structural and functional brain imaging 
(Rascovsky et al. 2011). The definite diagnosis is made either genetically i.e. by the detection 
of a pathological mutation or histologically via some recognized neuropathological 
characteristic in brain samples (Rascovsky et al. 2011). However, the diagnostics of bvFTD 
are particularly challenging and no biomarkers are available for clinical use. Neuroimaging 
findings may be normal even when the clinical picture indicates that there is at least moderate 
dementia (Riedl et al. 2014). In addition, variability in the clinical representation is seen in 
some families (Cooper-Knock, Shaw & Kirby 2014, Beck et al. 2013). It has been emphasized 
that patients suffering from early phases of bvFTD have a high risk of being misdiagnosed, 
being especially likely to be thought of as suffering from a psychiatric syndrome, because of 
the lack of deficits in episodic memory during the early stage of the disease   (Woolley et al. 
2011, Khan et al. 2012, Neary, Snowden & Mann 2005).  
Although there is no curative treatment for bvFTD, it is crucial that the patient should be 
correctly diagnosed. The diagnosis of bvFTD reduces human misery and helps the nursing 
personnel to empathize with this patient who has undergone such major changes in 
personality and behaviour. Furthermore, the response of the patients to antipsychotic 
treatment may be much worse than in truly psychotic patients, instead the bvFTD patients 
are likely to suffer the extrapyramidal side effects of these antipsychotic treatments 
(Karageorgiou, Miller 2014).  
The aim of this study was to evaluate the phenotype of bvFTD patients associated with 
the C9ORF72 expansion and the role of the mutation in psychiatric cohorts. It was decided to 
evaluate the latest diagnostic criteria for bvFTD patients with the C9ORF72 expansion, 
diagnosed in neurological outpatient clinics. The prevalence of the C9ORF72 expansion in 
cohorts of suicide victims and in subjects developing schizophrenia before the middle age 
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was also examined. In addition, the effect of the pathological C9ORF72 expansion was 
assessed in a family with genetically diagnosed Nasu-Hakola disease (NHD).   
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2 Review of literature 
2.1 FRONTOTEMPORAL LOBAR DEGENERATION 
 
FTLD is an umbrella term for progressive neurodegenerative diseases especially affecting 
frontal and temporal brain regions. FTLD is the second most common cause of early onset 
dementia i.e. in individuals under 65 years of age (Ratnavalli et al. 2002). From 5 to 15 % of 
the total number of patients suffering from dementia have FTLD (Cooper-Knock, Shaw & 
Kirby 2014). The prevalence of the FTLD is estimated to be generally 15 per 100 000 
(Ratnavalli et al. 2002), but in Finland, it can be as high as 20.5 per 100 000 (Luukkainen et al. 
2015). The onset of the disease is typically located in the middle-years of life and the mean 
survival time tends to be eight years (Neary, Snowden & Mann 2005).  
FTLD is divided into two major clinical syndromes - bvFTD and PPA, and this latter type 
is again sub-divided into two clinical subtypes, based on the clinical presentation. These are 
non-fluent variant primary progressive aphasia (nfvPPA), and semantic variant primary 
progressive aphasia (svPPA) (fig. 1) (Gorno-Tempini et al. 2011). In addition, the recently 
recognized logopenic variant of primary progressive aphasia (l-vPPA) (Gorno-Tempini et al. 
2008, Gorno-Tempini et al. 2011, Leyton et al. 2015) in clinical terms is reminiscent of other 
primary progressive aphasias, but actually cannot be exactly included under the umbrella of 
FTLD because the neuropathology and anatomical location of the atrophy resemble more 
Alzheimer’s disease (AD) than FTLD (Mesulam et al. 2008, Rabinovici et al. 2008, Leyton et 
al. 2015). BvFTD is the most common clinical syndrome of FTLD, accounting for over half of 
the cases (Johnson et al. 2005, Seelaar et al. 2008). At least 15% of the patients with FTLD 
develop motoneuron disease (MND) with amyotrophic lateral sclerosis (ALS) being the most 
common form of MND (Burrell et al. 2011). Approximately 15% of patients with MND 
develop FTLD (Ringholz et al. 2005). 
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Figure 1. FTLD and its subtypes. FTLD=frontotemporal lobar degeneration, bvFTD= behavioural 
variant frontotemporal dementia, PPA= primary progressive aphasia, nfvPPA= non-fluent 
variant primary progressive aphasia, svPPA= semantic variant primary progressive aphasia, 
lvPPA= logopenic variant primary progressive aphasia. 
 
The mean onset of the initial symptoms of the FTLD spectrum disorders is between 53 and 
61 years of age (Rosso et al. 2003, Nunnemann et al. 2011, Ratnavalli et al. 2002, Hodges et al. 
2003, Johnson et al. 2005). However, a later onset of the symptoms, even at the age of 80 years, 
has been reported (Rosso et al. 2003, Johnson et al. 2005). In contrast, patients developing 
FTLD in their thirties, have also been described (Mackenzie et al. 2008). The mean age at the 
time of diagnosis is somewhat later i.e. between 56 and 65 years (Nunnemann et al. 2011, 
Ratnavalli et al. 2002, Hodges et al. 2003).  Typically, the disease course of FTLD means that 
the patient will require institutionalization soon after the initial diagnosis (Hodges et al. 
2003). The mean age at death is around 65-67 years (Nunnemann et al. 2011, Hodges et al. 
2003, Johnson et al. 2005) as the duration from onset of the symptoms to death is between six 
to twelve years (Rosso et al. 2003, Nunnemann et al. 2011, Hodges et al. 2003) but also slower 
disease progression, i.e. as long as 20 years have been recorded (Rosso et al. 2003, Suhonen 
et al. 2015). The time period from the initial diagnosis to death tends to be between three to 
seven years (Hodges et al. 2003, Nunnemann et al. 2011).  No difference of survival has 
detected between the clinical FTLD syndromes with the exception of the FTLD-ALS 
subgroup, which has a clearly shorter survival, compared to patients without features of ALS 
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(Hodges et al. 2003). The cause of the death in FTLD patients is typically a respiratory system 
disorder, a circulatory system disorder or cachexia (Nunnemann et al. 2011).  
FTLD is not only neuropathologically heterogeneous but the genetic causes also vary 
(Neary, Snowden & Mann 2005). It has been estimated that 30-50% of the cases are of familial 
autosomal dominant source (Rosso et al. 2003, Rohrer et al. 2009, Ratnavalli et al. 2002, Ikeda, 
Ishikawa & Tanabe 2004) but bvFTD seems to be more familial than the other subtypes of 
FTLD (Rohrer et al. 2009). 
Certain procedures can help in the diagnosis of in FTLD i.e. neuroimaging (structural and 
functional), neuropsychological test batteries, clinical examination (especially careful 
neurological examination), biochemical analyses of cerebrospinal fluid and genetic screening 
of previously identified pathogenic mutations. Neuropathological biopsies may also be 
utilized in the diagnostic procedures. However, the diagnosis has remained challenging. 
(Neary et al. 1998, Rascovsky et al. 2011) 
Although there are only limited benefits gained from pharmacologic-biological treatments 
(in practice, there are only palliative therapies) the disease exerts a great strain on social 
relationships. For this reason, the education for patients and caregivers combined with 
psychosocial support remain as the cornerstone of the clinical management of FTLD.  
 
 
2.1.1 Historical aspects  
The first patient with the clinical syndrome of FTLD was described in 1892 by Arnold Pick, a 
neurologist practicing in Prague. The first case suffered from the symptoms of presenile 
dementia, aphasia and lobar atrophy (Pick 1892). Soon after the initial case, the syndrome 
was referred to as Pick disease. The neuropathological inclusions associated with previously 
described clinical phenotype, initially characterized by Alois Alzheimer in 1911, were named 
as Pick bodies. In following years, the term “Pick disease” was extended to comprise 
syndromes associated with atrophy in frontal lobar regions and dysfunction of frontal and 
temporal brain areas (Onari, Spatz 1926). In 1957 and 1974, pioneering studies reported the 
clinical and anatomical distinctions between Alzheimer’s disease (AD) and Pick disease; the 
atrophy was observed in more frontal areas in Pick disease whereas in AD it tended to occur 
more in posterior regions of brain (Delay, Brion & Escourolle 1957, Constantinidis, Richard 
& Tissot 1974). These studies also observed that only a small proportion of cases with Pick 
disease had classical Pick bodies in their brains and extrapyramidal symptoms were present 
quite often. The term of Pick disease was modernised so that it would refer to the frontal lobe 
degeneration of non-Alzheimer (FLDnA) type and the first conference on FLDnA was held 
in 1987 in Sweden (1987) followed by second conference in 1993 (1993).  The classification of 
memory diseases is presented in the figure 2. 
From the 1890s until the 1980s, only a few case reports described an unusual progressive 
aphasia associated with frontal neurobehavioural syndromes. In 1982, Mersel Mesulam 
published a case series describing gradually progressing aphasia without generalized 
dementia and thus established the language subtype of FTLD in patients with predominant 
atrophy in the left hemisphere (Mesulam 1982).  
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In 1990, Neary and colleagues indicated that “FLDnA” and ALS shared distinct 
pathological and clinical features (Neary et al. 1990). Soon thereafter, they also found that 
even in the same families, there was a significant variability in the clinical symptoms 
encompassing both behavioural and language disturbances (Neary, Snowden & Mann 1993). 
The behavioural variant syndrome was mainly studied in Lund, Sweden and Manchester, 
United Kingdom and thus the first clinical and pathological criteria for bvFTD  were called 
the Lund-Manchester criteria (The Lund and Manchester Groups 1994) (see table 1), and they 
focussed on the non-aphatic form of frontotemporal dementia (FTD). These first criteria 
originally coined the name “Frontotemporal dementia”. As the clinical data on FTD 
increased, the criteria were revised by Neary and colleagues (Neary et al. 1998) (see table 2). 
In addition, language variants of the FTLD were included into these criteria and furthermore, 
the ALS was taken into account as a supportive feature of FTD, hence these two syndromes 
were formally placed under the same umbrella. Subsequently, research on FTD has 
progressed dramatically and during recent years, after new gene identifications and new 
neuroimaging and biochemical methods, knowledge of FTLD has advanced almost 
exponentially. Rather recently, the diagnostic criteria were revised for bvFTD and language 
forms of FTLD to take into consideration the expanded understanding of FTLD (Rascovsky 
et al. 2011, Gorno-Tempini et al. 2011).  
 
Figure 2. The classification of dementing diseases. AD= Alzheimer’s disease, VD= vascular 
dementia, FTLD= frontotemporal lobar degeneration, LBD= Dementia with Lewy bodies, *E.g. 
Parkinson’s dementia, Alcohol related dementia, Huntington’s disease, Creutzfeldt-Jakob 
disease. 
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2.1.2 Behavioural variant frontotemporal dementia 
BvFTD is characterized with personality changes, delusions/hallucinations, disinhibition, 
apathy or inertia and deficits in executive tasks with relative sparing of memory functions 
(Cooper-Knock, Shaw & Kirby 2014, Rascovsky et al. 2011). Patients are often distractible and 
may lose their jobs (Karageorgiou, Miller 2014). It is common that the patients have a 
diminished ability to feel/express empathy or sympathy (Rascovsky et al. 2011) e.g.  they may 
ignore acute health problems of their spouses, due to a lack of empathy (Karageorgiou, Miller 
2014). It has been reported that stealing is one of the symptoms of bvFTD (Miller et al. 1997, 
Mendez 2011). Recently, two studies reported that criminality is very common in the early 
course of bvFTD, perhaps as many as 50% of the patients had committed crimes during the 
early course of their disease with the most common crimes being traffic violations, sexual 
advances, theft, wilful damage to property, housebreaking, trespassing and violence toward 
people/assault (Diehl-Schmid et al. 2013a, Liljegren et al. 2015).  
 
2.1.2.1 Diagnostic criteria for bvFTD 
The diagnostic instruments have only started to appear in the most recent decades.  Four sets 
of bvFTD criteria have been presented (The Lund and Manchester Groups 1994, Neary et al. 
1998, McKhann et al. 2001, Rascovsky et al. 2011) (see tables 1 for Lund and Manchester 
criteria, 2 for Neary’s criteria and 3 for Rascovsky’s criteria). It should be stated that 
McKhann’s criteria never became widely used whereas Neary’s criteria were most 
extensively applied until the introduction of latest set of criteria by Rascovsky and colleagues 
(Rascovsky et al. 2011). Unfortunately, there are no practical or actual biomarkers which 
correlate with the Rascovsky criteria for bvFTD (Rascovsky et al. 2011). 
In 2007, Rascovsky and colleagues stated that the current prevailing Neary criteria (Neary 
et al. 1998) were somewhat rigid and limited to clinical and scientific use (Rascovsky et al. 
2007). These Neary criteria included 5 core features, 20 supportive features, 11 exclusion 
features and 3 relative exclusion features thus making the clinical usage quite challenging. It 
has been stated frequently that the prompt and accurate diagnosis is pivotal for several 
reasons i.e. correct patient management (Perry, Miller 2001, Robinson 2001, Talerico, Evans 
2001, Merrilees, Miller 2003, Merrilees 2007, Boutoleau-Bretonniere et al. 2008), to ensure the 
patient receives appropriate treatment and to assist in the development of disease modifying 
drugs. The insensitivity of Neary’s criteria in the early stages of bvFTD  has been reported by 
several groups (Mendez, Perryman 2002, Mendez et al. 2007b, Rascovsky et al. 2007, Piguet 
et al. 2009) as at least one third of the actual bvFTD patients do not meet these criteria 
(Mendez, Perryman 2002) and a substantial amount of the patients with actual bvFTD have 
been classified as “normal”, or alternatively as psychiatric or AD-patients (Mendez et al. 
1993, Mendez et al. 2007b, Varma et al. 1999). Furthermore, the nomenclature and definitions 
of the features in the criteria were considered as vague. In addition, the progress in 
neuroimaging and genetic research provided new and more effective tools for the diagnosis 
of bvFTD (Rascovsky et al. 2011).  
The International Behavioural Variant FTD Criteria Consortium (FTDC) devised a new 
diagnostic battery for clinical and research use (Rascovsky et al. 2011). These FTDC criteria 
with its three levels of diagnostic certainty (i.e. possible, probable and definite) are presented in 
table 3. These criteria are based on behavioural symptoms, neuropsychological assessment, 
brain imaging (structural and functional) genetic tests and neuropathological analysis. Figure 
3 displays a typical positron emission tomography (PET) finding in FTLD. 
According to the FTDC criteria for neurodegenerative disease, other causes such as 
delirium, cerebrovascular disease, cerebellar disorder, trauma, infection, systemic disorder, 
substance-induced conditions, need to be excluded. In addition psychiatric conditions, which 
explain better the patient’s symptoms, are exclusion criteria for bvFTD (Rascovsky et al. 
2011). According to the FTDC criteria, bvFTD should be excluded, if cerebrospinal fluid (CSF) 
biomarkers or genetic data, e.g. amyloid precursor protein gene (APP) or presenilin (PSEN) 
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1 or 2 mutations causing familial AD (Gatz et al. 2006), are indicative of some other brain 
degenerative diseases (Rascovsky et al. 2011).  
Initially, the FTDC revised criteria were found to display 76% sensitivity for probable and 
86% for possible bvFTD among neuropathologically confirmed cases, while Neary criteria 
were found to have only 53% sensitivity. Subsequently, a large autopsy-based study 
indicated even better sensitivities, i.e. 95% for possible bvFTD and 85 % for probable bvFTD 
(Harris et al. 2013). One study, based on a clinically gathered cohort (Costa et al. 2013), 
revealed extremely high sensitivities, as high as 100%, for possible bvFTD, but however, only 
60% for probable bvFTD.  This study may have been biased by the selection of the patients 
as the study cohort only consisted of those patients with clearly evident bvFTD. The FTDC 
criteria were initially suggested to be less sensitive in patients with a later onset of the disease; 
this was explained by the lower rates of disinhibition, less extensive loss of sympathy or 
empathy, fewer perseverative behaviours and milder imaging findings consistent with 
bvFTD (Rascovsky et al. 2011).  
 
 
 
Figure 3. Typical frontal hypoperfusion in FDG-PET.  
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Table 1. The Lund and Manchester clinical criteria for frontotemporal dementia 1. 
Core diagnostic features of frontotemporal dementia 
Behavioural disorder 
• Insidious onset and slow progression 
• Early loss of personal awareness (neglect of personal hygiene and grooming) 
• Early loss of social awareness (lack of social tact, misdemeanours such as 
shoplifting) 
• Early signs of disinhibition (such as unrestrained sexuality, violent behaviour, 
inappropriate jocularity, restless packing) 
• Mental rigidity and inflexibility 
• Hyperorality (oral/dietary changes, overeating, food fads, excessive smoking and 
alcohol consumption, oral exploration of objects) 
• Stereotyped and perseverative behaviour (wandering, mannerisms such as clapping, 
singing, dancing, ritualistic preoccupation such as hoarding, toileting, and dressing) 
• Utilisation of behaviour (unrestrained exploration of objects in the environment) 
• Distractibility, impulsivity, and impersistence 
• Early loss of insight into the fact that the altered condition is due to a pathological 
change of own mental state. 
Affective symptoms 
• Depression, anxiety, excessive sentimentality, suicidal and fixed ideation, delusion 
(early and evanescent) 
• Hypochondriasis, bizarre somatic preoccupation (early and evanescent) 
• Emotional unconcern (emotional indifference and remoteness, lack of empathy and 
sympathy, apathy) 
• Amimia (inertia, aspontaneity). 
Speech disorder 
• Progressive reduction of speech (aspontaneity and economy of utterance) 
• Stereotypy of speech (repetition of limited repertoire of words, pharases, or themes) 
• Echolalia and perseveration 
• Late mutism. 
Spatial orientation and praxis preserved (intact abilities to negotiate the environment). 
Physical signs 
• Early primitive reflexes 
• Early incontinence 
• Late akinesia, rigidity, tremor 
• Low and labile blood pressure 
Investigations 
• Normal EEG despite clinically evident dementia 
• Brain imaging (structural or functional, or both): predominant frontal or anterior 
temporal abnormality, or both 
• Neuropsychology (profound failure on “frontal lobe” tests in the absence of severe 
amnesia, aphasia, or perceptual spatial disorder). 
Supportive diagnostic features 
• Onset before 65 
• Positive family history of similar disorder in a first degree relative 
• Bulbar palsy, muscular weakness and wasting, fasciculations (motor neuron 
disease). 
Diagnostic exclusion features 
• Abrupt onset with ictal events 
• Head trauma related to onset 
• Early severe amnesia 
• Early spatial disorientation, lost in surroundings, defective localisation of objects 
• Early severe apraxia 
• Logoclonic speech with rapid loss of train of thought 
• Myoclonus 
• Cortical bulbar and spinal deficits 
• Cerebellar ataxia 
• Choreo-athetosis 
• Early, severe, pathological EEG 
• Brain imaging (predominant post-central structural or functional deficit. Multifocal 
cerebral lesions on CT or MRI) 
• Laboratory tests indicating brain involvement or inflammatory disorder (such as 
multiple sclerosis, syphilis, AIDS and herpes simplex encephalitis). 
Relative diagnostic exclusion features 
• Typical history of chronic alcoholism 
• Sustained hypertension 
• History of vascular disease (such as angina, claudication). 
1According to the Lund and Manchester Groups (1994). 
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Table 2. Neary consensus criteria for frontotemporal dementia1. 
I. Core diagnostic features 
A) Insidious onset and gradual progression 
B) Early decline in social interpersonal conduct 
C) Early impairment in regulation of personal conduct 
D) Early emotional blunting 
E) Early loss of insight 
II. Supportive diagnostic features 
A) Behavioral disorder 
1. Decline in personal hygiene and grooming 
2. Mental rigidity and inflexibility 
3. Distractibility and impersistence 
4. Hyperorality and dietary changes 
5. Perseverative and stereotyped behaviour 
6. Utilization behaviour 
B) Speech and language 
1. Altered speech output 
a. Aspontaneity and economy of speech 
b. Press of speech 
2. Stereotypy of speech 
3. Echolalia 
4. Perseveration 
5. Mutism 
C) Physical signs 
1. Primitive reflexes 
2. Incontinence 
3. Akinesia, rigidity, and tremor  
4. Low and labile blood pressure 
D) Investigations 
1. Neuropsychology: significant impairment on frontal lobe tests in the absence of 
severe amnesia, aphasia, or perceptuospatial disorder 
2. Electroencephalography: normal on conventional EEG despite clinically evident 
dementia 
3. Brain imaging (structural and/or functional): predominant frontal and/or anterior 
temporal abnormality 
1According to Neary and colleagues (Neary et al. 1998). Criteria for language variants and features for 
common clinical syndromes in FTLD, discussed in original article, not included in this table. 
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Table 3. Current prevailing FTDC diagnostic criteria for bvFTD1. 
I. Neurodegenerative disease 
Patient must show a progressive deterioration of behaviour and/or cognition by observation or 
history. 
II. Possible bvFTD 
In order to meet the criteria for possible bvFTD, three of the following behavioural or 
cognitive symptoms (A-F) must be present. As a general guideline, “early” refers to symptom 
presentation within the first three years. 
E) Early behavioural disinhibition 
A1) Socially inappropriate behaviour 
A2) Loss of manners or decorum 
F) Early apathy or inertia 
B1) Apathy 
B2) Inertia 
G) Early loss of sympathy or empathy 
C1) Diminished responsiveness to other people’s needs and feelings 
C2) Diminished social interest, interrelatedness or personal warmth 
H) Early perseverative, stereotyped or compulsive/ritualistic behaviour 
D1) Simple repetitive movements 
D2) Complex, compulsive or ritualistic behaviours 
D3) Stereotypy of speech 
I) Hyperorality and dietary changes 
E1) Altered food preferences 
E2) Binge eating, increased consumption of alcohol or cigarettes 
E3) Oral exploration or consumption of inedible objects 
J) Neuropsychological profile: executive/generation deficits with relative sparing of memory 
and visuospatial functions 
F1) Deficits in executive tasks 
F2) Relative sparing of episodic memory 
F3) Relative sparing of visuospatial skills 
III. Probable bvFTD 
In order to meet the criteria for probable bvFTD, a patient must meet the criteria for possible 
bvFTD (A), plus both of the following (B and C) 
A) Meet criteria for possible bvFTD 
B) Exhibits significant functional decline (demonstrated by caregiver report or instruments 
e.g. CDR2, FAQ3, DAD4, AMPS5) 
C) Imaging results consistent with bvFTD 
C1) Frontal and/or anterior temporal atrophy on MRI or CT 
C2) Frontal and/or anterior temporal hypoperfusion or hypometabolism on PET or SPECT 
IV. Definite bvFTD 
In order to meet criteria for bvFTD with definite pathology, a patient must present with A, 
plus one of the following (B-C) 
A) Possible or probable bvFTD 
B) Histopathological evidence of FTLD on biopsy or at post-mortem 
C) Presence of a known pathogenic mutation 
V. Exclusionary criteria 
A diagnosis of bvFTD may not be given if the patient presents with any of the following (A-B).  
A) Pattern of deficits is better accounted for other non-degenerative nervous system or 
medical disorder 
B) Behavioural disturbance is better accounted for by a psychiatric diagnosis 
C) Biomarkers strongly indicative of Alzheimer’s disease or other neurodegenerative process 
1According to Rascovsky and colleagues 2011 (Rascovsky et al. 2011); 2Clinical Dementia Rating Scale; 
3Functional Activities Questionnaire; 4Disability Assessment for Dementia; 5Assessment of Motor of Motor 
or Process Skills. 
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2.1.2.2 Differential diagnosis and diagnostic challenges of bvFTD 
The challenge of the diagnosis of FTD is reflected in the rather long latency between the onset 
of symptoms and the eventual diagnosis, approximately from three to four years (Diehl-
Schmid et al. 2007) even though the revised diagnostic criteria (FTDC criteria) have been 
proven to have high sensitivity (Rascovsky et al. 2011).During the early stages of the disease, 
patients may perform normally in neuropsychological tests of language and memory, and 
even executive functions may remain spared (Riedl et al. 2014). However, it could be argued 
that the nomenclature misleads clinicians as the FTLD is included and discussed under the 
umbrella term of memory diseases. Moreover, radiologists occasionally misinterpret the 
magnetic resonance imaging (MRI) of the patient, failing to recognize the pattern of atrophy 
(Karageorgiou, Miller 2014) and structural brain imaging may also display quite subtle or 
apparently age-dependent changes (Riedl et al. 2014). 
The first symptoms are rather unspecific and may suggest the appearance of a psychiatric 
disorder (Riedl et al. 2014). The symptoms of bvFTD include apathy (Rascovsky et al. 2011) 
and patients tend to withdraw socially and lose interest in everyday activities (Riedl et al. 
2014). Family members often (mis-)interpret patient as being depressed (Karageorgiou, 
Miller 2014). Thus, perhaps most often, the typical misdiagnosis is that the bvFTD patient is 
suffering from some psychiatric disease, especially a mood disorder or schizophrenia 
(Galimberti et al. 2015). In addition, patients with extremely slow progression (survival 
lasting as long as decades from initial symptoms) tend to be misdiagnosed primarily for 
psychiatric disorders (Khan et al. 2012). As a consequence, a detailed psychiatric examination 
is required or at least highly recommended to exclude psychiatric etiology for the patient’s 
symptoms (Rascovsky et al. 2011).  
Another differential diagnostic challenge is to distinguish between bvFTD and frontal type 
AD, especially in elderly patients. Neuropsychological examination, fludeoxyglucose 
positron emission tomography (FDG-PET), molecular PET and CSF biomarkers are useful 
ways to discriminate bvFTD from AD (Riedl et al. 2014, Karageorgiou, Miller 2014). The 
neuropsychological examination in bvFTD often reveals a relative sparing of memory and 
visuospatial functions (Rascovsky et al. 2011) whereas deficits in memory are the most 
characteristic symptom of early AD. Structural imaging (MRI) may not be specific to ensure 
a differential diagnosis, because hippocampal atrophy, which has been traditionally 
considered as a feature of AD (Dickerson et al. 2001, Killiany et al. 2002),  is seen in both AD 
and FTLD (Barnes et al. 2006, Josephs, Dickson 2007, Lindberg et al. 2012). FDG-PET may be 
useful in borderline cases by revealing glucose hypometabolism in corresponding regions of 
brain (Riedl et al. 2014). Molecular PET, using amyloid antibody, is indicative for AD 
(Drzezga et al. 2008, Rabinovici et al. 2007, Karageorgiou, Miller 2014). With regard to CSF 
biomarkers, high tau levels in CSF are claimed to be specific for AD (Bibl et al. 2011) as well 
as tau/amyloid beta(42) ratio (Bian et al. 2008). However, in the C9ORF72 expansion 
associated FTLD, a reduced Aβ1-42 level has been detected in 25% of cases (Kamalainen et 
al. 2015). 
A remarkable amount of the patients suffer from features of Parkinson’s Disease (PD) at 
the initial stage clinical assessment of bvFTD (Le Ber et al. 2006). When the patient’s motor 
symptoms consist of axial rigidity, relative sparing of the arms and a lack of tremor as well 
as other features of bvFTD being present, then he/she may be thought to be suffering from 
corticobasal syndrome (CBS) (Karageorgiou, Miller 2014). In fact, the cortical symptoms of 
CBS overlap with those of bvFTD (Armstrong et al. 2013, Litvan et al. 1996). 
2.1.3 Primary progressive aphasias 
PPA is subdivided according to the clinical findings, into three subcategories: nfvPPA, 
svPPA and logopenic variant primary progressive aphasia (l-vPPA) (Gorno-Tempini et al. 
2011).  
Before being classified into one of these subcategories of PPA, the patient must first meet 
the criteria for “general” PPA, devised initially by Mesulam and colleagues (Mesulam 2001), 
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see table 4. PPA has an insidious onset and speech and language tasks are gradually impaired 
(Gorno-Tempini et al. 2011). The most prominent initial symptoms are disturbances in 
language (aphasia) i.e. problems in word-finding, impairment of word comprehension, 
abnormalities of word-order or other grammatic disturbances (Mesulam et al. 2009). During 
the initial phases of PPA, activities of daily living (excluding activities that require language) 
are maintained (Gorno-Tempini et al. 2011). 
The PPA diagnosis can be established by describing the specific impairments in language 
and speech to classify the disorder into one of three subcategories. All these diagnoses can 
be made with the three different levels of certainty: 1) clinical, 2) imaging supported or 3) 
definite pathological diagnosis (Gorno-Tempini et al. 2011).  
 
 
 
 
Table 4. Inclusion and exclusion criteria for the diagnosis of PPA1. 
I. Inclusion: criteria 1-3 must be answered positively 
1. Most prominent clinical feature is difficulty with language 
2. These deficits are the principal cause of impaired daily living activities 
3. Aphasia should be the most prominent deficit at symptom onset and for the initial phases 
of the disease 
II. Exclusion: criteria 1-4 must be answered negatively for a PPA diagnosis 
1. Pattern of deficits is better accounted for by some other nondegenerative nervous system 
or medical disorder 
2. Cognitive disturbance is better accounted for by a psychiatric diagnosis 
3. Prominent initial episodic memory, visual memory, and visuoperceptual impairments 
4. Prominent, initial behavioural disturbance 
1According to Mesulam and colleagues 2011 (Mesulam 2001). 
 
 
2.1.3.1 Non-fluent variant primary progressive aphasia  
NfvPPA is characterized with difficulties in word retrieval, nonfluent speech patterns and a 
progressive loss of speech (Cooper-Knock, Shaw & Kirby 2014, Neary et al. 1998). The 
language production is agrammatic and speech is “apractic” but single word comprehension 
and object knowledge are spared (see table 5) (Gorno-Tempini et al. 2011).  Thus, it may be 
considered as a Broca-like syndrome (Kirshner 2014). Cognitive tests may show mild 
impairment in working memory and executive functions (Gorno-Tempini et al. 2004). 
Behavioural disturbances are not as common as in bvFTD or svPPA, but these symptoms 
may have been observed, especially during the later stages of the disease (Rosen et al. 2006). 
Left side posterior fronto-insular atrophy is often detected (Grossman et al. 1996, Gorno-
Tempini et al. 2004, Nestor et al. 2003, Josephs et al. 2006).  
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Table 5. Diagnostic features for the nfvPPA1. 
I. Clinical diagnosis of nonfluent/agrammatic variant PPA 
At least one of the following core features must be present: 
1. Agrammatism in language production 
2. Effortful, halting speech with inconsistent speech sound errors and distortions (apraxia of 
speech) 
At least 2 of 3 of the following other features must be present: 
1. Impaired comprehension of syntactically complex sentences 
2. Spared single-word comprehension 
3. Spared object knowledge 
II. Imaging-supported nonfluent/agrammatic variant PPA diagnosis 
Both of the following criteria must be present 
1. Clinical diagnosis of nonfluent/agrammatic variant PPA 
2. Imaging must show one or more of the following results: 
a) Predominant left posterior fronto-insular atrophy on MRI or 
b) Predominant left posterior fronto-insular hypoperfusion or hypometabolism in SPECT or 
PET 
III. Nonfluent/agrammatic variant PPA with definite pathology 
Clinical diagnosis (criterion 1 below) and either criterion 2 or 3 must be present 
1. Clinical diagnosis of nonfluent/agrammatic variant PPA 
2. Histopathological evidence of a specific neurodegenerative pathology (e.g., FTLD-tau, 
FTLD-TDP, AD, other) 
3. Presence of a known pathogenic mutation 
1According to Gorno-Tempini et al. 2011. 
 
 
 
 
 
 
2.1.3.2 Semantic variant primary progressive aphasia  
Loss of memory regarding the understanding of words and objects is the main characteristic 
feature encountered in svPPA (Cooper-Knock, Shaw & Kirby 2014, Neary et al. 
1998)(Cooper-Knock, Shaw & Kirby 2014)(Cooper-Knock, Shaw & Kirby 2014). Motor and 
grammar speech are often spared as well as is word repetition (Gorno-Tempini et al. 2011) 
(see table 6). The word loss often appears gradually as first non-familiar words are lost and 
as the disease progresses, these disturbances develop into multimodal agnosia (Hodges et al. 
1992, Neary et al. 1998, Gorno-Tempini et al. 2011). Patients with svPPA display a significant 
amount of behavioural disturbances (Rosen et al. 2006). Anatomical damage is located in 
ventral and lateral portions of the anterior temporal lobes bilaterally, but often the atrophy 
is more severe on the left side (Gorno-Tempini et al. 2004, Mummery et al. 2000, Mesulam et 
al. 2009, Galton et al. 2001, Rosen et al. 2002b).  
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Table 6. Diagnostic criteria for the semantic variant PPA1. 
I. Clinical diagnosis of semantic variant PPA 
At least one of the following core features must be present: 
1. Impaired confrontation naming 
2. Impaired single-word comprehension 
At least 3 of the following other diagnostic features must be present: 
1. Impaired object knowledge, particularly for low-frequency or low-familiarity items 
2. Surface dyslexia or dysgraphia 
3. Spared repetition 
4. Spared speech production (grammar and motor speech) 
II. Imaging-supported semantic variant PPA diagnosis 
Both of the following criteria must be present 
1. Clinical diagnosis of semantic variant PPA 
2. Imaging must show one or more of the following results: 
a) Predominant anterior temporal lobe atrophy 
b) Predominant anterior temporal hypoperfusion or hypometabolism in SPECT or PET 
III. Semantic variant PPA with definite pathology 
Clinical diagnosis (criterion 1 below) and either criterion 2 or 3 must be present: 
1. Clinical diagnosis of semantic variant PPA 
2. Histopathological evidence of a specific neurodegenerative pathology (e.g., FTLD-tau, 
FTLD-TDP, AD, other) 
3. Presence of a known pathogenic mutation 
1According to Gorno-Tempini et al. 2011. 
 
 
 
2.1.3.3 Logopenic variant primary progressive aphasia  
LvPPA is characterized by impaired repetition of sentences and phrases and reduced single-
word retrieval in spontaneous speech combined with spared motor speech, absence of frank 
agrammatism, and spared object knowledge (see table 7) (Gorno-Tempini et al. 2011).  It has 
been estimated that approximately 2.6% of all FTLD patients suffer from lvPPA (Ioannidis et 
al. 2012). Imaging reveals the presence of atrophy in the left temporal parietal junction area 
(Gorno-Tempini et al. 2004, Gorno-Tempini et al. 2008, Gorno-Tempini et al. 2011). Moreover, 
the AD pathology seems to be most common among the lvPPA-patients (Mesulam et al. 2008, 
Rabinovici et al. 2008). 
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Table 7. Diagnostic criteria for logopenic variant PPA1. 
I. Clinical diagnosis of logopenic variant PPA 
Both of the following core features must be present: 
1. Impaired single-word retrieval in spontaneous speech and naming 
2. Impaired repetition of sentences and phrases 
At least 3 of the following other features must be present: 
1. Speech (phonologic) errors in spontaneous speech and naming 
2. Spared single-word comprehension and object knowledge 
3. Spared motor speech 
4. Absence of frank agrammatism 
II. Imaging-supported logopenic variant PPA diagnosis 
Both criteria must be present 
1. Clinical diagnosis of logopenic variant PPA 
2. Imaging must show one or more of the following results: 
a) Predominant left posterior perisylvian or parietal atrophy on MRI 
b) Predominant left posterior perisylvian or parietal hypoperfusion or hypometabolism in 
SPECT or PET 
III. Logopenic variant PPA with definite pathology 
Clinical diagnosis (criterion 1 below) and either criterion 2 or 3 must be present: 
1. Clinical diagnosis of logopenic variant PPA 
2. Histopathological evidence of a specific neurodegenerative pathology (e.g., FTLD-tau, 
FTLD-TDP, AD, other) 
3. Presence of a known pathogenic mutation 
1According to Gorno-Tempini et al. 2011. 
 
 
 
 
 
 
 
2.1.4 Epidemiology 
The diagnostic criteria have been revised during the last years due to the rapid development 
of neuroimaging and genetic techniques revealing the presence of the pathogenic mutations 
behind FTLD. However, the epidemiologic data of the FTLD is sparse. The genetic factors 
contributing to FTLD vary in different geographical areas which may indicate that the 
prevalence also is subject to wide diversity. FTLD had been awarded an “orphan disease” 
status (Orpha number ORPHA282 of http://orphan.net) as the disease was suspected to be 
quite rare. However, a few reports, describing the epidemiology of the disease, have been 
published and it is becoming apparent that perhaps FTLD is not at as “orphan” as previously 
hypothesized.  
The incidence of FTLD is 2.2 per 100 000 person-years at age 40-49, 3.3 per 100 000 person-
years at age 50-59 and rises to 8.9 per 100 000 person-years in the 60-69 age bracket (Johnson 
et al. 2005). The estimated point prevalence is 15-22 per 100 000 inhabitants (Onyike, Diehl-
Schmid 2013). In Finland, the prevalence of FTLD has been determined to be higher as a 
recent study estimated it to be 20.5 per 100 000 in 45-65 year olds, rising to 26.8 per 100 000 
at 45-70 years (Luukkainen et al. 2015). However, it has been proposed that the calculated 
prevalences have been underestimated due the inadequate recognition of FTLD syndromes 
by psychiatrists, psychologists and primary care physicians (Galimberti et al. 2015). There is 
no significant gender difference in FTLD patients, but overall there is a trend towards male 
predominance (Rosso et al. 2003, Nunnemann et al. 2011, Ratnavalli et al. 2002, Hodges et al. 
2003).  
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2.1.5 Genetics 
A positive family history of FTLD in the patients has been observed in 40-50% of the cases 
(Lashley et al. 2011, Rosso et al. 2003, Hodges et al. 2003). Approximately 20% of the patients 
exhibit an autosomal dominant pattern of inheritance (Rosso et al. 2003). The bvFTD has been 
estimated to have up to 30-50% inheritability and thus bvFTD displays more profound 
inheritability than the language variants (Seelaar et al. 2008, Chow et al. 1999, Goldman et al. 
2005, Rosso et al. 2003, Stevens et al. 1998, Rohrer et al. 2009). FTD-ALS has been estimated 
to have 10-60% heritability (Seelaar et al. 2008, Goldman et al. 2005, Rohrer et al. 2009). The 
autosomal dominant pattern of inheritance has identified in genes encoding for microtubule 
associated protein tau (MAPT), progranulin (GRN), c9orf72, valosin containing protein 
(VCP), charged in multivesicular body protein 2B (CHMP2B), TARDBP and fused in sarcoma 
(FUS) proteins (Sieben et al. 2012). Nonetheless, a high proportion of families with FTLD have 
remained genetically unidentified (Seelaar et al. 2011). For proportions of known genetic 
factors, see table 8.  
 
Table 8. Gene mutations and their proportions in the FTLD.   
Gene  
C9ORF72 
GRN 
MAPT 
CHMP2B 
VCP 
FUS 
TARDBP 
TMEM106 
Proportion (%) 
14-48 
3-26 
0-50 
<1 
<1 
Extremely rare 
Extremely rare 
Extremely rare 
Data adopted from Sieben and colleagues (Sieben et al. 2012). 
 
2.1.5.1. The C9ORF72 expansion 
The C9ORF72 expansion is the most common genetic cause of familial and sporadic FTLD 
and ALS (Renton et al. 2011, DeJesus-Hernandez et al. 2011). In Finland, the frequency of the 
C9ORF72 expansion is one of the highest in the world and it has been stated to explain nearly 
50 % of familial FTLD in the Finnish population cases (Renton et al. 2011, DeJesus-Hernandez 
et al. 2011, Majounie et al. 2012b). The pathogenic C9ORF72 expansion leads to TDP-43 
neuropathology (DeJesus-Hernandez et al. 2011), but in the clinic, extensive diversity is 
observed in the C9ORF72 expansion associated FTLD phenotype (Cooper-Knock, Shaw & 
Kirby 2014, Beck et al. 2013). The characteristics of the C9ORF72 expansion are reviewed in 
chapter 2.2.  
 
2.1.5.2 GRN 
The autosomal dominant loss-of-function mutations in GRN account from 3 to 26 % of 
familial FTLD cases (Baker et al. 2006, Cruts et al. 2006, Sieben et al. 2012) but these mutations 
are very rare in Finland (Kruger et al. 2009). The normal function of the progranulin protein 
is to act as a growth factor in wound healing and tumour growth inflammation, and it is seen 
frequently in neuronal tissues (Ahmed et al. 2007).  Mutations have been detected throughout 
the gene, but the pathological syndrome is attributable to mutations leading to loss-of-
function alleles (Yu et al. 2010). This suggests that haploinsufficiency of GRN is a pathological 
process. The neuropathological findings in GRN associated FTLD have been associated with 
the TAR-DNA binding protein of 43 kDa (TDP-43) pathology (Snowden et al. 2015). This type 
of pathology will be described in greater detail in section 2.1.7.2.  
There is substantial diversity seen in onset age, disease duration and symptoms among 
the GRN mutation carriers (Seelaar et al. 2011). The mean age at the onset is around 60 years 
(range 35 to 89) and the mutation achieves about 90% penetrance by the age of 70 years (van 
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Swieten, Heutink 2008, Gass et al. 2006). The most characteristic feature of these patients is 
apathy and social withdrawal (Seelaar et al. 2011). Hallucinations and delusions are often 
reported (Le Ber et al. 2008, Benussi et al. 2008, Boeve et al. 2006). The clinical picture often 
includes extrapyramidal symptoms (Ghetti et al. 2015, Karageorgiou, Miller 2014). ALS is a 
rarely observed in the carriers of pathologic GRN mutation (Gass et al. 2006, Kelley et al. 2009, 
Beck et al. 2008, Pickering-Brown et al. 2008). The phenotype may be bvFTD, PPA, or CBS 
(Galimberti, Scarpini 2012).  
2.1.5.3 MAPT 
A mutation in MAPT has been observed in patients with FTLD and its incidence has been 
determined to be very diverse i.e.  from being extremely rare to being present in as many as 
50% of familial FTLD cases (Sieben et al. 2012). This gene is located in chromosome 17q locus 
21 (Wilhelmsen et al. 1994, Foster et al. 1997). The MAPT mutation leads to impaired 
composition of microtubules because of hyperphosphorylation of tau, impaired axonal 
transport and this mutation also causes pathological tau aggregation in neurons/glial cells 
(Riedl et al. 2014, Seelaar et al. 2011, Brandt, Hundelt & Shahani 2005, Hutton et al. 1998). 
More than 40 mutations have been detected in familial FTD and Parkinsonism cases (Hutton 
et al. 1998), but also microdeletion of MAPT is known commonly to cause mental retardation 
in patients of European heritage (Koolen et al. 2006). In addition, one de novo mutation has 
been presented in the literature (Boeve et al. 2005). Some recessive and sporadic cases have 
also been reported (van Swieten, Spillantini 2007). The frequency of the mutation varies 
between populations with the highest frequencies being encountered in the Netherlands and 
the UK (Pickering-Brown et al. 2008, Seelaar et al. 2008, Rohrer et al. 2009). In contrast, the 
mutation is very rare in Finland, detected only in one family (Skoglund et al. 2008).  
The MAPT mutation associated FTLD has been claimed to have a rather early onset (Le 
Ber 2013). The mean age at the onset of the initial symptoms has been estimated to be 55 years 
(van Swieten, Spillantini 2007), although the range of onset age ranges from under 40 to older 
than 70 years (van Swieten, Spillantini 2007). The MAPT mutations are clinically linked to 
features of Parkinsonism and oculomotor dysfunction (Le Ber 2013). Two core phenotypes 
are encountered among the carriers of this mutations (Seelaar et al. 2011) 1) dementia-
dominant phenotype with prominent behavioural changes (disinhibition and obsessive-
compulsive behaviour) (van Swieten, Spillantini 2007) and 2) parkinsonism-dominant 
phenotype with CBS or progressive supranuclear palsy (PSP) -like syndromes (van Swieten, 
Heutink 2008). The psychotic features are not observed among pathologic MAPT mutation 
carriers (Snowden et al. 2015).   
 
2.1.5.4 Other genetic factors 
Other hereditary etiological factors associated with FTLD are mutations in genes encoding 
for four proteins - CHMP2B, VCP, FUS and TARDBP.  
The mutation in the CHMP2B gene (Skibinski et al. 2005) is responsible for only a small 
number of familial FTLD cases (Cannon et al. 2006, Rizzu et al. 2006). The exact function of 
the CHMP2B gene has not yet been identified. Neuropathological and 
immunohistochemistry analyses have revealed the presence of ubiquitin-reactive inclusions 
negative for TDP-43 and FUS antibodies (Holm et al. 2007, Holm, Isaacs & Mackenzie 2009) 
and the pathological classification leads to FTLD-UPS (Majounie et al. 2012b).The mean onset 
of the CHMP2B gene associated FTLD is between 46 to 65 years (Gydesen et al. 2002, Isaacs 
et al. 2011). According to one carefully described Danish family, the penetrance is suspected 
to be almost complete (Gydesen et al. 2002). Most often, the CHMP2B gene mutation leads to 
the bvFTD syndrome, characterized by a global cognitive impairment, Parkinsonism, 
dystonia, pyramidal signs and myoclonus (Gydesen et al. 2002). Clinical ALS has been 
reported in only two patients (Gydesen et al. 2002). Language deficits are often perceived, 
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but these are quite mild and thus the diagnosis of svPPA or nfvPPA cannot be made 
(Gydesen et al. 2002).   
Mutations in VCP are rare and 17 mutations in VCP have been found in about 40 different 
families (Sieben et al. 2012, Seelaar et al. 2007). The neuropathology of the patients carrying 
the VCP mutation tends to be TDP-43 proteinopathy (Weihl 2011). Mutations in VCP have 
been associated with three clinical presentations: 1) inclusion body myopathy, which almost 
always can be found in the clinical presentation, 2) Paget´s disease of the bone, which is seen 
in nearly every second patient, and, 3) FTLD, which is present in approximately one third of 
the patients.  The age at the onset of clinical FTLD syndrome is estimated to be between 40 
and 60 years (Watts et al. 2004, Kimonis et al. 2008).  
A mutation in TARDBP gene in chromosome 1 has been identified as being responsible 
for five percent of the inheritance of ALS (Yokoseki et al. 2008, Benajiba et al. 2009, 
Sreedharan et al. 2008, Daoud et al. 2009, Kabashi et al. 2008, Rutherford et al. 2008). Several 
patients carrying this mutation have been observed to have bvFTD or FTD-ALS syndrome 
(Benajiba et al. 2009, Borroni et al. 2009).  
In addition, mutations in the FUS gene have been claimed to be the cause of approximately 
5% of the familial ALS cases (Vance et al. 2009, Kwiatkowski et al. 2009, Chio et al. 2009, 
Groen et al. 2010) and one patient carrying this mutation with clinical bvFTD has been 
reported (Van Langenhove et al. 2010). The onset of the symptoms takes place when the 
patients are in their thirties or forties (Lashley et al. 2011). A recent genome wide association 
study revealed also risk gene “transmembrane protein 106b” (TMEM106B) in chromosome 
7p21 which was claimed to elevate the risk for FTLD-TDP (Van Deerlin et al. 2010). However, 
the vast majority of genetic factors remain to be identified.  
 
2.1.6 Neuropathology 
As the clinical picture of FTLD syndromes is attributable to several rather different types of 
mutations, also neuropathological findings display diversity. However, different 
neuropathological patterns share some distinct commonalities.  
First, the brain atrophy is seen predominantly in the frontal, insular or anterior temporal 
lobar areas (Boccardi et al. 2005, Bocti et al. 2006, Davies et al. 2009, Du et al. 2007, Frisoni et 
al. 1996, Grossman et al. 2004, Kipps et al. 2009, Lindberg et al. 2009, Perry et al. 2006, 
Richards et al. 2009, Rosen et al. 2002a, Schroeter et al. 2008, Seeley et al. 2008, Short et al. 
2005, Whitwell et al. 2009, Whitwell, Jack 2005). In some patients, there is asymmetric atrophy 
which is mainly reflected in perisylvian loss on one side of the brain (Cairns et al. 2007).  
Neuropathologically FTLD may be divided into tau positive and tau negative cases (figure 
4). Tau negative cases are divided again into TDP-43-positive, ubiquitin positive 
histopathology and TDP-43-negative, ubiquitin-positive FUS-positive histopathology. The 
fourth subtype is called FTLD-UPS and it is associated with the presence of ubiquitin-
positive, FUS and TDP-43 –negative inclusions and perhaps even some cases without 
detectable inclusions (Riedl et al. 2014, Mackenzie et al. 2010, Pikkarainen, Hartikainen & 
Alafuzoff 2010, Pikkarainen, Hartikainen & Alafuzoff 2008).  
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Figure 4. The pathologies and their subtypes in FTLD. PiD = Pick disease, PSP = progressive 
supranuclear palsy, CBD = corticobasal degeneration, AGD = argyrophilic grain disease and 
MSTD = multiple system taupathy with dementia.  
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2.1.6.1 FTLD-tau 
In global terms, FTLD-tau represents approximately 40% of the FTLD pathologies (Riedl et 
al. 2014). The normal function of tau is to be a component of microtubules in the cytoskeleton 
of cells. Microtubules are also important factors in intracellular trafficking between somal 
and axonal regions of the nerves (Goedert 2004). In pathological conditions, the tau proteins 
in microtubules are hyperphosphorylated and this leads to the destruction of microtubules 
and further to the formation of insoluble tau aggregates, called neurofibrillary tangles in 
neurons and glial cells (Goedert 2004). These neurofibrillary tangles are the same as those 
seen in AD (Cairns et al. 2007). FTLD-tau pathology includes FTD-patients with MAPT 
mutations, Pick disease, PSP, corticobasal degeneration (CBD), argyrophilic grain disease 
and multiple system taupathy with dementia (MSTD) (Mackenzie et al. 2010, Riedl et al. 
2014). If there is widespread distribution of neurofibrillary tangles, this is indicative of MSTD 
(Bigio et al. 2001). When neurofibrillary tangles are located chiefly in subcortical regions, then 
PSP is more likely. CBD is characterized by the presence of astrocytic plaques and abundant 
thread pathology (Riedl et al. 2014). Interestingly, the FTLD-tau pathology due the MAPT 
mutation is neuropathologically variable as different types of tau isoforms have been 
detected in neuronal and glial pathology (van Swieten, Spillantini 2007, Cairns et al. 2007). 
FTLD-tau represents mostly clinically bvFTD, but also nfvPPA and features of 
Parkinsonism are also observed, whereas svPPA and combined ALS are very rare (Josephs 
et al. 2011). The FTLD-tau pathology is believed to have a shorter survival compared to tau-
negative FTLD (Xie et al. 2008). 
 
 
2.1.6.2 FTLD-TDP 
TDP is the most common neuropathology in FTLD (Lipton, White & Bigio 2004, Taniguchi 
et al. 2004) and it has been observed in familial and sporadic cases with and without ALS 
(Cairns et al. 2007). The FTLD-TDP pathology is characterized by the abnormal accumulation 
of TDP-43. The physiological functions of TDP-43 consist of exon skipping and transcription 
regulation (Cairns et al. 2007). In pathological conditions, the TDP-43 protein is abnormally 
phosphorylated, ubiquitinated and cleaved, and hence generating C-terminal fragments 
(Neumann et al. 2006), which form ubiquitin positive inclusions, called S204. TDP-43 
neuropathology is associated with p62 and ubiquitin positive inclusions (Arai et al. 2003, 
Jackson, Lennox & Lowe 1996, Pikkarainen, Hartikainen & Alafuzoff 2008). 
FTLD-TDP may be practically divided into four subtypes (Sampathu et al. 2006, 
Mackenzie et al. 2006, Cairns et al. 2007). However, an overlap between subtypes has been 
reported (Boeve, Lang & Litvan 2003). The first subtype, called TDP pathology type A, is 
reflected by the presence of abundant dystrophic neurites and is associated mostly to PPA. 
The second subtype (TDP pathology type B) is characterized with numerous neuronal 
cytoplasmic inclusions in superficial and cortical laminae. This subtype is fundamentally 
associated with the FTD-ALS phenotype. The third subtype (TDP-pathology type C) consists 
from numerous cytoplasmic inclusions, dystrophic neurites and neuronal intranuclear 
inclusions. This subtype is associated with the GRN mutation. Type C is usually detected in 
cases with svPPA. The fourth subtype (TDP-pathology type D) is characterized by numerous 
intranuclear and an infrequent number of neuronal cytoplasmic inclusions and dystrophic 
neurites. This subtype is associated with VCP mutation (Sampathu et al. 2006, Cairns et al. 
2007, Arai 2014). The C9ORF72 expansion associated neurodegenerative disease leads 
usually to TDP-43 neuropathology. The most common subtypes of TDP-43 neuropathology 
linked to this mutation are type A (Murray et al. 2011, Mann et al. 2013, Josephs et al. 2013) 
and type B (Al-Sarraj et al. 2011, Boxer et al. 2011, Murray et al. 2011, Snowden et al. 2012) 
and although  type C has been reported, it is very rare (Josephs et al. 2013).  
Patients with FTLD-TDP-pathology typically have bvFTD, nfvPPA or svPPA. The most 
cases of svPPA represent FTLD-TDP pathology. Furthermore, concomitant ALS symptoms 
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are indicative for underlying FTLD-TDP pathology although Parkinsonism is rare (Josephs 
et al. 2011, Arai 2014). 
 
 
2.1.6.3 FTLD-FUS 
FTLD-FUS accounts for around 5-10% of the FTLD neuropathologies (Mackenzie et al. 2008). 
The neuropathological finding is characterized by neuronal cytoplasmic inclusions and 
dystrophic neurites in the superficial layers of the frontotemporal neocortex, and dentate 
granule cells of the hippocampus (Mackenzie, Rademakers & Neumann 2010). The inclusions 
are immunoreactive for FUS antibody (Neumann et al. 2009, Seelaar et al. 2010, Neumann et 
al. 2011). The normal function of FUS protein is consisted from DNA repair and the 
regulation of DNA splicing (Vance et al. 2009, Kwiatkowski et al. 2009). Cases with FTLD-
FUS pathology tend to be sporadic (Seelaar et al. 2010, Josephs et al. 2010) and interestingly 
these patients do not carry the FUS gene mutation (Urwin et al. 2010).  
Patients with FTLD-FUS pathology are often young at the onset of the symptoms and the 
clinical disease subtype is bvFTD. However, also older patients with FUS pathology have 
been reported (Hartikainen et al. 2012).  
 
2.1.6.4 FTLD-UPS 
FTLD-UPS neuropathology is rare and the pathological inclusions are only demonstrated 
with nonspecific markers of the ubiquitin proteasome system and possibly in some cases no 
inclusions are even detected (Riedl et al. 2014). The inclusions are negative for FUS and TDP-
43 (Seelaar et al. 2011). Most of the cases with FTLD-UPS pathology have been reported to 
carry the CHMP2B mutation  (Holm et al. 2007, Holm, Isaacs & Mackenzie 2009, Urwin et al. 
2010), but also cases with FTLD-UPS pathology without that mutation are possible (Urwin et 
al. 2010).  
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2.1.7 Nasu-Hakola disease 
NHD (polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, 
Online Mendelian inheritance in Man, OMIM 221770) is a rare autosomal recessive disease, 
first described by Nasu (Nasu, Tsukahara & Terayama 1973) in Japan and Hakola (Hakola, 
Iivanainen 1973) in Finland.  The core signs of NHD are painful lipomembranotic cystic 
lesions in distal bones in the early adulthood (the mean age of 27 years) and progressive brain 
atrophy combined with personality changes followed a few years later by a cognitive decline 
(at the mean age of 33 years) (Hakola, Iivanainen 1973, Hakola 1990, Paloneva et al. 2001).  
This results in frontal type dementia and leads to death at the mean age of 43 years (Paloneva 
et al. 2001) and thus may be placed clinically under the umbrella of FTDs. At the present time, 
fewer than 300 cases have been described in the literature.  
NHD is divided into four stages: 1) latent phase, 2) osseous phase, 3) early neurological 
and 4) late neurological phase. The latent phase is asymptomatic and neurological 
development does not differ from healthy controls. The first symptoms observed by the 
patient, are pain and tenderness, mostly in ankles and feet leading to first pathological 
fracture at a mean age of 27 years. This period, when only fractures are present, is called the 
osseous phase (Paloneva et al. 2001). The fractures tend to heal well, but X-ray reveals 
trabecular bone loss in the distal ends of the long tubular bones accompanied by a symmetric 
cystic lesion in the phalanges (Makela et al. 1982, Paloneva et al. 2001). At the mean age of 33 
years, the personality starts to change and the disease stage is called the early neurological 
phase. The neuropsychological symptoms are predominantly frontal, including loss of 
judgement, disinhibition, euphoria, difficulties in concentration, lack of insight, lack of libido 
and motor persistence. These symptoms lead to social problems (e.g. divorce, unemployment 
or financial troubles). Alterations in memory are less severe than personality changes 
(Paloneva et al. 2001) and hence NHD neurologically resembles bvFTD especially in the early 
neurological phase.  At the same time, a progressive upper motor neuron involvement starts 
to appear. The last stage is called the late neurological phase with symptoms of motor 
aphasia, agraphia, acalculia and apraxia. The ability to walk is lost at the mean age of 42 
years, leading to a vegetative stage, including the appearance of primitive reflexes (Paloneva 
et al. 2001).  Epilepsy may be seen, although not frequently, during the disease course 
(Kaneko et al. 2010). 
Neuroimaging reveals sclerosing leukoencephalopathy, calcification in basal ganglia 
(mostly in the putamina), a small head of caudate nuclei, diffuse brain atrophy and white 
matter changes (Kilic et al. 2012, Paloneva et al. 2001). Reduced blood flow is seen bilaterally 
in frontal and temporal lobes as well as in thalamus and basal ganglia (Takeshita et al. 2005).  
Glucose hypometabolism is also seen at the corresponding areas in PET scan (Ueki et al. 2000) 
and precuneus hypoperfusion may be observed in single photon emission computed 
tomography (SPECT) imaging of brain (Nakamagoe et al. 2011). Subsequent blood-brain 
barrier breakdown is found in autopsies, which may be related to alterations in the 
microcirculation (Paloneva et al. 2001).  
There are two known pathological mutations believed to be linked with this disease: 
DAP12 (DNAX activation protein of 12 kDa, known also as TYROBP) and TREM2 (Triggering 
receptor expressed on myeloid cells 2). Homozygous mutations are required for disease 
development. Both of these mutations are pivotal for the widespread variety of myeloid and 
lymphoid lineage cells, for example for microglial and osteoclast functions (Paloneva et al. 
2002, Colonna 2003, Paloneva et al. 2000).  DAP12 causes the NHD cases in Finland and 
mostly in Japan, but TREM2 has been detected in cases located in other parts of the world 
(Klunemann et al. 2005, Paloneva et al. 1993).  
DAP12 is a protein transmembrane adaptor protein mediating the activation of variety of 
cells of myeloid and lymphoid origin (Paloneva et al. 1993, Lanier et al. 1998). A heterozygous 
NHD case with DAP12 mutation has also been presented in the literature (Kuroda et al. 2007). 
TREM2 encodes the protein that is an activating cell surface protein that forms a complex 
with DAP12 (Paloneva et al. 1993, Klunemann et al. 2005). It has been postulated that a defect 
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in TREM2 could inhibit the phagocytosis by microglia leading to the accumulation of toxic 
metabolites in the extracellular space in the brain which can directly harm the brain tissue 
(Bock et al. 2013).   
Extensive variety is perceived in the phenotype of pathogenic TREM2 carriers (compared 
to DAP12). In particular, TREM2 is reported in frontotemporal-like family (Guerreiro et al. 
2013a) and in dementia without bone cystic lesions (Chouery et al. 2008, Guerreiro et al. 
2013c). It has been shown recently that heterozygous variants of TREM2 are associated with 
a significant risk increase of AD (Guerreiro et al. 2013b, Jonsson et al. 2013). While TREM2 
may lead to recessive autosomal clinical bvFTD, it is overexpressed in AD brains and is 
known to be part of the genetic etiology for NHD and therefore it has been assumed that 
TREM2 can evoke neurodegeneration in general (Giraldo et al. 2013). 
 
2.1.8 Treatment of FTLD 
There is no current pharmacological curative treatment available. However, several studies 
have evaluated the efficacy of memantine and anticholinesterase treatments (Moretti et al. 
2004, Mendez et al. 2007a, Lampl, Sadeh & Lorberboym 2004, Kertesz et al. 2008, Diehl-
Schmid et al. 2008, Vercelletto et al. 2011, Chow et al. 2011, Boxer et al. 2013), but no 
improvement in cognition or behaviour was attributable to the medication (Riedl et al. 2014) 
and in fact cholinesterase inhibitors may even worsen behavioural symptoms (Karageorgiou, 
Miller 2014). However, about 30-40% of the FTLD patients receive these treatments (Diehl-
Schmid et al. 2012, Bei et al. 2010).   
A few studies have evaluated whether dopaminergic drugs exert any benefits in FTLD 
(Huey et al. 2008, Reed et al. 2004, Rahman et al. 2006), but no improvements or reproducible 
results have been observed (Karageorgiou, Miller 2014, Riedl et al. 2014). Some atypical 
antipsychotic drugs may be beneficial in FTLD and positive effects of risperidone, olanzapine 
and aripiprazole have been reported (Curtis, Resch 2000, Fellgiebel et al. 2007, Moretti et al. 
2003), but these should be used with some caution in view of their extrapyramidal side effects 
(Karageorgiou, Miller 2014), in fact, FTLD patients may be more sensitive to these 
extrapyramidal symptoms. In addition, the evidence on efficacy is limited and there are no 
controlled studies on the benefits of antipsychotic treatment in FTLD in the literature (Riedl 
et al. 2014).  
Some positive results on drug efficacy have been described with serotonin uptake 
inhibitors in FTLD (Moretti et al. 2003, Deakin et al. 2004, Mendez, Shapira & Miller 2005, 
Lebert et al. 2004, Ikeda et al. 2004, Herrmann et al. 2012, Adler, Teufel & Drach 2003). These 
drugs may be useful for treating certain aspects of the disease e.g. compulsions, eating 
disorders, disinhibition, apathy, repetitive behaviours and sexually inappropriate 
behaviours (Riedl et al. 2014, Karageorgiou, Miller 2014).   
Family education programs, changes in the sleep schedule, social worker involvement in 
financial and legislative issues, evaluating the patient’s abilities to drive a car, physical 
exercise and speech therapy to maximize communication skills, have been seen as useful 
interventions (Karageorgiou, Miller 2014, Riedl et al. 2014). In addition, improving the 
awareness of FTLD through better training of health and social care professionals has been 
claimed to be an important issue (Diehl-Schmid et al. 2013b). Today, there are no 
international guidelines for the management of FTLD clinical syndromes. In Finland, current 
care guidelines for the treatment of memory disorders (www.kaupahoito.fi, 2010, referred 
January 28, 2016) recommend that anticholinergic drugs and memantine should be avoided. 
The management should consist of well performed care of other diseases, the avoidance of 
exacerbating factors (e.g. inappropriate pharmaceuticals, depression, poor nutrition), 
provision of symptomatic medication, regular follow-up, encouragement to participate in 
healthy activities, access to  supportive services (food services, cleaning services etc.) as well 
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as legislative issues (e.g. wills and testaments, trusteeship), and finally ensuring access of the 
patient to  financial and social benefits.   
In the future, targeted pharmacological treatments may become available based on the 
genetic etiology of the clinical syndrome.  
  
26 
 
 
2.2 CHARACTERISTICS OF THE C9ORF72 EXPANSION  
 
It has been known for a long time that FTD and ALS are intensely familial. About ten years 
ago, several pathogenic mutations (superoxide dismutase, SOD1; TAR DNA-binding protein 
43, TARDBP; FUS; Optineurin, OPTN and VCP) were identified as causing familial ALS, but 
these mutations accounted for only approximately 25% of all the familial cases. In 2006, a 
genetic linkage was identified between the familial ALS-FTLD families and short arm of 
chromosome 9 (Momeni et al. 2006, Morita et al. 2006, Vance et al. 2006, Boxer et al. 2011, 
Pearson et al. 2011). These findings were followed by a large genome wide association study 
(GWAS) in a Finnish population. This study revealed the chromosome 9p21 locus as a major 
cause of familial ALS in Finland (Laaksovirta et al. 2010) and the same locus was also 
identified as causative for familial FTLD (Van Deerlin et al. 2010). Interestingly, the identical 
“risk” haplotype was found in all populations (Mok et al. 2012), highlighting the special 
significance of that specific genetic region. Subsequently, two consortiums identified an 
expansion mutation in the chromosome 9 open reading frame 72 (C9ORF72) resulting the 
familial FTLD and ALS (fig. 5) (Renton et al. 2011, DeJesus-Hernandez et al. 2011). Today, the 
C9ORF72 expansion is known to be the most common genetic etiology for ALS and FTLD 
(Renton et al. 2011, DeJesus-Hernandez et al. 2011).  
 
 
 
 
Figure 5. The chromosome 9 open reading frame 72 gene and the repeat expansion. 
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2.2.1 Molecular biology of the C9ORF72 expansion 
The C9ORF72 gene, located on the short arm of chromosome 9 (9p21), encodes twelve exons 
and three different transcript variants. Those are generated by alternative splicing of 
messenger ribonucleic acid (mRNA). Of these splicing products, variants 1 and 3 encode for 
the longer protein isoform of the C9orf72 (481 amino acids, isoform a) and variant 2 encodes 
for the shorter (222 amino acids) isoform b (DeJesus-Hernandez et al. 2011). The normal 
region GGGGCC (G4C2) repeats is thought to be under 30 times (Renton et al. 2011). 
However, limits of 24 (van der Zee et al. 2013), 60 (Gijselinck et al. 2012) and 65 (Loy et al. 
2014) repeats have also been considered as a lower limit for pathological expansion numbers. 
In healthy subjects, the genome contains three copies of the repeat sequence (Smith et al. 
2013). The pathogenic form of the expansion is conventionally suspected to consist from 400 
up to thousands of repeats. The repeat region is located between two non-coding exons 1a 
and 1b situated in core promotor region of transcript variant 1 leading to loss of transcription 
and to a significant reduction of the amount of isoform a (Renton et al. 2011, DeJesus-
Hernandez et al. 2011). 
The C9orf72 protein has been postulated to localize in the cytoplasm of neurons and other 
cells and it is typically concentrated in synaptic terminals (Renton et al. 2011, DeJesus-
Hernandez et al. 2011). It has been proposed that the C9orf72 may be related to “differentially 
expressed in normal and neoplastic” (DENN)-like proteins, guanosine diphosphate/ 
guanosine triphosphate (GDP/GTP) exchange factor, which could lead to activation of rab-
GTPases which are involved in the maintenance of intracellular vesicular trafficking (Levine 
et al. 2013, Zhang et al. 2012). This finding has been reproduced 1) in in vitro studies in 
neuronal cell lines, 2) in mouse cultured neurons, and 3) in human spinal cord motor neurons 
from an ALS patient with the pathogenic C9ORF72 expansion (Farg et al. 2014). These studies 
revealed that C9orf72 is associated with Rab proteins in endosomal, lysosomal and 
autophagosomal vesicles. Furthermore, the co-localization of the C9orf72 and Rab proteins 
has been observed in ALS motor neurons. These data suggest that the abnormal function of 
the C9ORF72 gene leads to a disturbance in protein trafficking and degradation and thus may 
be involved in the pathogenesis of ALS and FTLD. The recent study in a zebrafish C9ORF72 
knockdown model revealed that the C9orf72 is expressed in nervous system during 
developmental stages. In addition, deficits in behaviour and locomotion were seen in fish 
with a lack of the C9ORF72 expression, but interestingly, those deficits could be rescued by 
overexpression of the human C9orf72 mRNA transcripts (Ciura et al. 2013). More specifically, 
the arborisation of neurons was disturbed and motor neuron axons were shortened. 
Therefore, it could be speculated that the loss of function of C9orf72 may cause ALS also in 
humans. The mouse 311004O21Rik gene (orthologous for the human C9ORF72 gene) is 
expressed widely in the neurons of central nervous system, including hippocampus, cortex 
and spinal cord, but not in the microglia or astrocytes (Suzuki et al. 2013).  
Three major competing molecular mechanisms have been postulated to be responsible for 
the C9ORF72 expansion associated pathogenesis of FTLD and ALS.  
The first mechanism emerges from the theory that the GGGGCC repeat produces nuclear 
aggregates that inhibit the normal function of several ribonucleic acid (RNA) -binding 
proteins and this consequently impairs the processing and stability of RNA (Mori et al. 2013b, 
Xu et al. 2013, Donnelly et al. 2013). Moreover, the RNA aggregates have been observed to 
be present in the neurons and fibroblasts of the C9ORF72 expansion carriers (DeJesus-
Hernandez et al. 2011, Lagier-Tourenne et al. 2013, Gendron et al. 2013). In addition, 
GGGGCC-containing toxic foci have been observed to associate with aberrant gene 
expression and this was proposed to lead to glutamate-induced excitotoxicity in a study 
conducted in neurons, differentiated from induced pluripotent stem cells from ALS patients 
(Donnelly et al. 2013). The same study revealed that those outcomes could be reversed with 
antisense oligonucleotide against the GGGGCC repeat of the C9ORF72 expansion. Treatment 
with the antisense oligonucleotide against the C9ORF72 expansion containing RNA was also 
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able to decrease the number of RNA foci in mouse central nervous system and human 
fibroblasts (Lagier-Tourenne et al. 2013).  
The second mechanism indicates that the C9ORF72 expansion results in the formation of 
repeat associated non-standard (RAN) translation products that lead to translation and 
accumulation of pathological polypeptides in neurons, and the formation of inclusion bodies. 
These inclusions have been seen to form from polypeptides containing dipeptide repeats of 
poly-glycine-alanine, poly-glycine-proline and poly-glycine-arginine (Ash et al. 2013, Mori 
et al. 2013a, Mori et al. 2013c). Recently it has been shown that the RNA may be translated 
also in an antisense direction resulting in the synthesis of poly-proline-arginine and poly-
proline-alanine containing dipeptide repeats (Gendron et al. 2013, Mori et al. 2013a). This 
hypothesis is supported by the findings that the histopathology of the FTLD includes 
intracytoplasmic accumulation of specific type proteins (Riedl et al. 2014). 
The third mechanism is based on the concept of haploinsufficiency of the C9ORF72 
expansion. Several studies have shown that patients carrying the C9ORF72 expansion have 
reduced levels of the normal gene transcripts in brain tissue as well as in fibroblasts and 
lymphoblasts. The mRNA levels of the transcription variants of both variants are reduced by 
up to 50% (DeJesus-Hernandez et al. 2011, Ciura et al. 2013, Gijselinck et al. 2012). The protein 
levels of the C9orf72 have also been shown to be reduced in the frontal cortex of ALS/FTLD 
patients (Waite et al. 2014). Intriguingly, also a recent study suggested that cell lines from 
ALS/FTLD patients have upregulated methylation in the expanded C9ORF72 area, leading 
to decreased levels of the transcription variants whereas methylation was not seen in the 
normal length C9ORF72 gene (Belzil et al. 2013). These findings indicate that the pathogenic 
expansion of the C9ORF72 may lead to disturbances of epigenetic regulation and hence 
decrease the normal C9orf72 protein levels. 
 The C9ORF72 expansion is associated with FTLD-TDP pathology, which has been 
described in 2.1.7.2. 
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2.2.2 Genetic epidemiology 
Approximately as many as 50% of the familial and 20% of sporadic FTLD cases are caused 
by the C9ORF72 repeat expansion. In addition, the expansion is responsible for up to 50% of 
familial ALS cases and 20 % of sporadic ALS cases (Majounie et al. 2012b, Cruts et al. 2013, 
van der Zee et al. 2013). Somewhat higher prevalences have been reported from Europe than 
in America. Moreover, in the Nordic countries, the prevalences of the diseases associated 
with the C9ORF72 expansion, have been estimated to be higher than in other parts of Europe. 
An extremely high prevalence of the C9ORF72 expansion has been observed in Finnish FTLD 
cases (Renton et al. 2011, DeJesus-Hernandez et al. 2011, Majounie et al. 2012b). Significantly 
lower prevalences are encountered among non-European descendants (Ishiura et al. 2012, 
Jang et al. 2013, Jiao et al. 2014b, Konno et al. 2013, Majounie et al. 2012b, Ogaki et al. 2012, 
Tsai et al. 2012, Zou et al. 2013). 
The same risk C9ORF72 haplotype has been found to be present in all populations, 
suggesting a single founder effect (Majounie et al. 2012b, Mok et al. 2012). Single nucleotide 
polymorphism (SNP) haplotype data estimated that the founder mutation occurred between 
1500 (Majounie et al. 2012b) and 6300 years ago (Smith et al. 2013). If one applies a realistic 
population growth estimate of between 2.5 and 8.5% and intergenerational intervals 
supported by historical evidence of between 20 to 30 years, the founder event is likely to be 
thousands of years old (Smith et al. 2013). Moreover, the high prevalences of the C9ORF72 
expansion in Finland and Sardinia are thought to be result from the genetic isolation of these 
populations (Heutink, Oostra 2002, Service et al. 2006).  
There is controversial data about the prevalence of the C9ORF72 expansion in the healthy 
population. The pathological length C9ORF72 expansion has not been detected in control 
cases in some studies (Cacace et al. 2013, Rollinson et al. 2012, Xi et al. 2012).  The prevalence 
of the C9ORF72 expansion was systematically analysed among the 54-year old healthy 
subjects in the UK. The prevalence was found to be 11/7,598 (resulting in 0.15% of healthy 
population) (Beck et al. 2013). Nonetheless, this result may not indicate the real prevalence 
among the lifetime-neurodegeneratively-healthy controls as the 50% penetrance of the 
mutation is seen not until the age of 58 (Majounie et al. 2012b) and full penetrance only seems 
to be present at the age of 80 (Benussi et al. 2014). Nonetheless, a few individuals have been 
reported to carry the pathogenic C9ORF72 expansion without any neurological, cognitive or 
psychiatric symptoms at the age of 80 years or more (Galimberti et al. 2014a). At the present, 
the question of whether the penetrance of the C9ORF72 expansion will be complete, remains 
slightly unresolved.  
 
2.2.3 The diseases involving the C9ORF72 expansion 
The C9ORF72 expansion is the most common genetic cause of familial FTLD and ALS cases 
(DeJesus-Hernandez et al. 2011, Renton et al. 2011). However, the C9ORF72 expansion has 
been speculated to associate with other neurodegenerative and psychiatric diseases and the 
phenotype of the mutation carriers has been established to be extremely variable (Cooper-
Knock, Shaw & Kirby 2014, Beck et al. 2013).   
 
2.2.3.1 Clinical aspects of the C9ORF72 expansion associated FTLD 
The C9ORF72 expansion is associated most commonly with the bvFTD phenotype (DeJesus-
Hernandez et al. 2011, Renton et al. 2011). This phenomenon has been noted in different 
populations around the world and bvFTD is believed to be more prevalent in the C9ORF72 
expansion associated FTLD than in the other  mutations  (Murray et al. 2011, Snowden et al. 
2012, Benussi et al. 2014, Ferrari et al. 2012, Dobson-Stone et al. 2012, Gijselinck et al. 2012, 
Boeve et al. 2012, Galimberti et al. 2013a, Sha et al. 2012, Kaivorinne et al. 2013, Hsiung et al. 
2012, Khan et al. 2012, Simon-Sanchez et al. 2012, Van Langenhove et al. 2013). NfvPPA is the 
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next common phenotype, but there is no clinical difference between the C9ORF72 expansion-
associated and non-C9ORF72 expansion associated nfvPPA syndromes. SvPPA is rarely seen 
among the C9ORF72 expansion carriers (Snowden et al. 2012, Simon-Sanchez et al. 2012, 
Cerami et al. 2013).  
The age at the onset of the disease seems to be somewhat lower in the C9ORF72 expansion 
carriers, compared to those with other genetic factors causing the FTLD, being around 58 
years (Snowden et al. 2012). A family history of early onset dementia or ALS is often seen 
with the C9ORF72 expansion (Snowden et al. 2012, Kaivorinne et al. 2013). A positive family 
history of these diseases more than doubles the likelihood of having the C9ORF72 expansion 
(Snowden et al. 2012, Kaivorinne et al. 2013, Devenney et al. 2014).  One third of the patients 
with the C9ORF72 expansion are classified as suffering from FTD-ALS. In fact, the C9ORF72 
expansion has remained almost the only recognized factor causing both FTLD and ALS 
(Snowden et al. 2012). The features of parkinsonism have been proposed to be more common 
among the C9ORF72 expansion carriers than in non-carriers (Devenney et al. 2014). 
Significant deficits in executive functions in combination with the relative sparing of 
episodic memory and visuospatial skills, are seen in the majority of patients with the 
expansion (Snowden et al. 2012, Devenney et al. 2014). Irrational behavioural disinhibition 
and apathy combined with a loss of insight are common features displayed by the C9ORF72 
expansion carriers. In addition, ritualistic/stereotypic behaviour is a distinctive trait of the 
carriers of this mutation. The dietary changes seem to be significantly more infrequent 
(Mahoney et al. 2012, Snowden et al. 2012, Sha et al. 2012). Anxiety/agitation, obsessionality, 
effortful speech, low mood, loss of empathy and echolalia are also seen among the C9ORF72 
expansion carriers (Mahoney et al. 2012).  
No statistically significant differences in survival between carriers and non-carriers have 
been observed, but all of the studies have noted a clear trend that there is an earlier onset of 
the symptoms (by a few years) in the C9ORF72 expansion carriers (Snowden et al. 2012, Sha 
et al. 2012, Devenney et al. 2014).  
The C9ORF72 expansion is believed to cause an increasingly earlier disease onset in 
successive generations within a pedigree (Benussi et al. 2014), which may explain the large 
variation in the phenotype of the C9ORF72 expansion associated phenotype. There are 
controversial findings about whether it is possible to relate the expansion size to the clinical 
phenotype. No convincing correlation between expansion size and clinical phenotype was 
detected in one study (Beck et al. 2013). In contrast, another study indicated that the number 
of expansions could be associated with the onset age of the disease (Benussi et al. 2014). 
In the C9ORF72 expansion associated bvFTD, psychoses are undoubtedly more prevalent 
especially during the early course of the disease and this may even be considered to be a part 
of the “core phenotype” of the mutation (Snowden et al. 2012, Sha et al. 2012, Devenney et 
al. 2014). In addition, two studies comparing mutation carriers and non-carriers among the 
bvFTD patients, detected a higher frequency of psychosis in the C9ORF72 expansion carriers 
compared to sporadic cases. Thus psychosis has been claimed to be the best discriminating 
feature between the C9ORF72 expansion carriers and non-carriers (Galimberti et al. 2013a, 
Kertesz et al. 2013).  In a study consisting of 32 patients with the C9ORF72 expansion, 
psychiatric disturbances were seen in 69% of the bvFTD cases whereas those symptoms were 
seen only in less than 4% of the bvFTD cases without the mutation, resulting in high statistical 
significance between these two groups (Snowden et al. 2012). In more detail, 38% of the 
patients with the C9ORF72 expansion exhibited florid psychotic symptoms. These patients 
had received an initial psychiatric diagnosis such as delusional psychosis, somatoform 
psychosis or paranoid schizophrenia. Several patients also suffered from somatic symptoms 
without medical cause and some others presented with confused/ frankly bizarre behaviour. 
It was considered noteworthy, that no previous history (before the initial symptoms of 
bvFTD) of psychiatric disease had been identified. The delusional symptoms failed to 
respond to anti-psychotic medication (Snowden et al. 2012). Typically psychotic symptoms 
seem to be paranoid type delusions and hallucinations. These results are somewhat 
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controversial as there seems to be extensive variation in the incidence of hallucinations i.e. 
from being very rare to being present in up to 50% of the cases among the C9ORF72 
expansion carriers (Boeve et al. 2012, Simon-Sanchez et al. 2012).  
The presence of psychiatric illness in the family has been claimed to be significantly more 
prevalent among the C9ORF72 expansion carriers than in patients with other mutations 
associated with FTLD (Devenney et al. 2014).  
 
 
2.2.3.2 Motoneuron disease  
MND due the C9ORF72 expansion or in more specific terms in the most common form of 
MND, ALS, is a rapidly progressive neurodegenerative disorder characterized by 
degeneration in motor neurons in cerebral cortex, brainstem and spinal cord (Brooks et al. 
2000). The disease begins first with muscle weakness, then proceeds to atrophy and paralysis 
of muscles resulting in death within 3-5 years from onset of the disease, typically due to 
respiratory failure (Rowland, Shneider 2001, McDermott, Shaw 2008). ALS is estimated to 
affect 6/100 000 persons (Ticozzi et al. 2011) and 5-10 % of the cases are familial (Byrne et al. 
2011). The incidence of ALS in Finland is one of the highest in the world, i.e. 2.4 per 100 000 
person years (Cronin, Hardiman & Traynor 2007).  
Both limb and bulbar onset ALS are seen among the C9ORF72 expansion carriers (Cooper-
Knock et al. 2012, Gijselinck et al. 2012, Murray et al. 2011). Patients carrying other mutations 
causing ALS, have a higher than expected concurrence with the C9ORF72 expansions (van 
Blitterswijk et al. 2012), which may indicate oligogenic inheritance of ALS. 
A significant proportion of the C9ORF72 expansion carriers suffer from the combined 
disease of FTD and ALS and consequently the C9ORF72 expansion is present in most of the 
FTD-ALS cases (Murray et al. 2011, Van Langenhove et al. 2013, Gijselinck et al. 2012, Hsiung 
et al. 2012, Cooper-Knock et al. 2012, Debray et al. 2013, Ratti et al. 2012, Stewart et al. 2012, 
Kaivorinne et al. 2013). The presence of the ALS with FTD more than doubles the likelihood 
that the patient will be carrying the C9ORF72 expansion (Snowden et al. 2012). 
If one examines FTD-ALS patients, then it seems that there is a lower proportion of the 
C9ORF72 expansion carriers that meet the FTDC criteria, compared to non-carriers (Sha et al. 
2012). The C9ORF72 expansion carriers may express less depressive symptoms than non-
carriers and furthermore these patients have a longer survival in comparison with FTD-ALS 
without this expansion (Sha et al. 2012). 
In the neuroimaging assessment, the C9ORF72 expansion carriers with FTD-ALS exhibited 
greater dorsal frontal and posterior cortical atrophy, as well as atrophy of the cerebellum. On 
the other hand, non-carriers displayed more ventral and temporal lobe involvement than the 
C9ORF72 expansion carriers. In addition, the C9ORF72 expansion carriers seem to have more 
atrophy in the right thalamus than non-carriers (Sha et al. 2012).   
 
2.2.4 Other diseases with a putative connection with the C9ORF72 expansion 
Soon after the finding of C9ORF72 expansion, an increasing number of scientific reports have 
described the possible connections with different neurodegenerative diseases which share 
some common features. For instance, the C9ORF72 expansion has been found in some cases 
with AD, sporadic Creutzfeldt-Jakob disease, Huntington’s disease (HD) phenocopy, and 
Parkinson plus diseases (Loy et al. 2014, Beck et al. 2013).  
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2.2.4.1 Alzheimer’s disease  
The C9ORF72 expansion has been found also in some patients with clinical AD, but the 
findings have been somewhat controversial.  The presence of mutation has been estimated 
to be only around 1% in families with late onset clinical AD, even in neuropathologically 
confirmed AD cases (Majounie et al. 2012a, Cacace et al. 2013, Wojtas et al. 2012, Beck et al. 
2013, Harms et al. 2013, Bieniek et al. 2014, Jiao et al. 2014a, Kohli et al. 2013). However, these 
findings could not be confirmed in other studies (Xi et al. 2012, Rollinson et al. 2012, Jiao et 
al. 2013). One group failed to detect this mutation in an extensive cohort of patients with mild 
cognitive impairment (MCI) (Cacace et al. 2013).  
It has been proposed that the variety of phenotypes in bvFTD patients with the C9ORF72 
expansion associated bvFTD could include AD –like symptoms (Adeli et al. 2014). Moreover, 
the differential diagnosis between AD and bvFTD may be challenging as the CSF findings in 
patients carrying the C9ORF72 expansion have pointed towards AD since there are reduced 
levels of beta amyloid and an elevated amount of tau and phosphorylated tau (Wallon et al. 
2012, Kamalainen et al. 2015). It has been postulated that the presence of the C9ORF72 
expansion in AD may simply be coincidental (Davidson et al. 2013) or that the C9ORF72 
expansion may contribute to the pathogenesis of AD (Kohli et al. 2013).  
 
 
2.2.4.2 Huntington’s disease  
HD is an autosomal dominant disorder; it is the most common cause of classical chorea 
(Walker 2007). The clinical features of the HD include movement disorders, mainly chorea, 
psychiatric symptoms and a progressive cognitive decline leading to dementia (Walker 
2007). BvFTD and HD share some common symptoms e.g. cognitive and psychiatric 
disturbances. In HD, the gene mutation is located on chromosome 4p16.3 with the type of 
mutation being a trinucleotide expansion (over 39 expansions) of CAG (The Huntington's 
Disease Collaborative Research Group 1993). Nonetheless, a substantial number of patients 
with clinical HD deliver a negative result from genetic testing and those clinical subtypes are 
termed as HD-like disorders (Moore et al. 2001).  
The C9ORF72 expansion has been detected in 1.7% of HD patients in the UK (Beck et al. 
2013) and the C9ORF72 expansion has been estimated as being the most common cause of 
HD phenocopy syndrome (Koutsis et al. 2015, Kostic et al. 2014, Hensman Moss et al. 2014). 
The expansion sizes have been somewhat similar for other diseases associated with the 
C9ORF72 expansion, but the onset age has had a lower tendency, even including one 
paediatric case, indicating that the penetrance of the C9ORF72 expansion may be even earlier 
than previously thought in some infrequent cases.  
 
 
2.2.4.3 Parkinson’s disease and other motor disorders  
Parkinsonism is present in up to 35% of the C9ORF72 expansion carriers and an increased 
risk of Parkinsonism has been identified in their relatives  (Boeve et al. 2012, Cruts et al. 2013, 
Takada et al. 2012, Savica et al. 2012, Luigetti et al. 2013, Hsiung et al. 2012, Van Langenhove 
et al. 2013). A recent meta-analysis of the role of the C9ORF72 expansion in PD concluded 
that the C9ORF72 expansion appeared to be specific for FTD/ALS and it was not associated 
with idiopathic PD (Theuns et al. 2014), but the role of intermediate repeats of the C9ORF72 
has remained unresolved. The intermediate length, but not the large repeat numbers, of the 
C9ORF72 expansion has been proposed to be a contributing factor for PD and essential 
tremor plus Parkinsonism i.e. its presence elevates the subject’s risk of developing these 
syndromes (Nuytemans et al. 2013).  
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2.2.4.4 Psychiatric disorders and suicidal behaviour 
The bvFTD patients exhibit a wide diversity of neuropsychiatric symptoms. Hence, it has 
been proposed in some studies that there is an association between the C9ORF72 expansion 
and certain psychiatric conditions. 
The C9ORF72 expansion has been speculated to be a rare cause of schizophrenia 
(Galimberti et al. 2014b, Watson et al. 2016) and there are several case reports describing the 
extremely florid psychiatric symptoms of subjects with the C9ORF72 expansion associated 
bvFTD (Holm 2014, Gramaglia et al. 2014, Sommerlad et al. 2014). Nonetheless, a few studies 
have detected no connection with the C9ORF72 expansion and schizophrenia (Yoshino et al. 
2014, Huey et al. 2013, Fahey et al. 2014). In addition, the results seem to depend on the 
geographical location of the screened population. Patients carrying the C9ORF72 expansions 
are thought to be at an elevated risk of receiving an erroneous psychiatric diagnosis prior to 
the correct one because they might not display any neurological symptoms in fact, the 
presenting symptoms at the early disease course may be exclusively psychiatric (Gramaglia 
et al. 2014). 
Some studies have reported the possible connection of the C9ORF72 expansion and bipolar 
disorder (Floris et al. 2013, Meisler et al. 2013, Galimberti et al. 2013b) suggesting that there 
is a 0.5-1.0 % prevalence in bipolar disorder patients. However, a later screening in 206 
Sardinian patients suffering from bipolar disease did not detect any abnormal expansions. 
These researchers suggested that the C9ORF72 expansion could affect the early 
neurodevelopment and later it could be involved in neurodegeneration, predisposing the 
individual to bipolar disorder or alternatively bipolar disorder could even be a prodromal 
phase of the bvFTD (Floris et al. 2014).   
There are several reports that there is a possible connection between suicide and bvFTD 
(Alberici et al. 2012, Mendez, Bagert & Edwards-Lee 1997). Moreover, a suicide attempt is 
proposed to be a putative symptom of bvFTD and the odds ratio value shows that suicidal 
behaviour may be more common among subjects with bvFTD compared to their age and 
gender matched controls (Fonseca et al. 2014). The same study also revealed that depressive 
episodes elevate the risk for suicide attempt in bvFTD. One interesting hypothesis was 
proposed by Synofzik and colleagues; they speculated that in particular the C9ORF72 
expansion associated early dementia could cause suicide as a presenting symptom. They also 
suggested that the relatively high rate of apparently sporadic bvFTD patients associated with 
the C9ORF72 expansion could be explained by the fact that suicides in the other bvFTD 
patients may have gone unreported or alternatively these subjects had not been diagnosed 
with bvFTD prior to their suicide (Synofzik et al. 2012).  
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3 Aims of the study 
The main goal of this thesis was to extend our understanding of the spectrum of clinical 
symptoms and the core phenotypes due the C9ORF72 expansion. As the C9ORF72 expansion 
is known to cause many neuropsychiatric symptoms, the aim was to evaluate the presence 
of these symptoms. Another aim was to assess the applicability of the revised FTDC criteria 
for bvFTD among the Finnish C9ORF72 expansion carriers.  
As there is an extensive overlap in the symptoms of schizophrenia and bvFTD, especially 
when bvFTD is due the C9ORF72 expansion, the prevalence of this mutation was analysed 
in the cohort of patients with early onset schizophrenia. In addition, suicide has been 
repeatedly proposed to be a presenting symptom of bvFTD, especially in the C9ORF72 
expansion associated syndrome. Thus, the prevalence of the C9ORF72 expansion was 
analysed in a well characterized cohort of victims of suicide. The role of the C9ORF72 
expansion in clinical presentation of NHD was also evaluated. 
 
 
 
The specific aims of the thesis were: 
 
 
1. To describe the sensitivity of FTDC criteria among the C9ORF72 expansion carriers 
(I). 
 
 
2. To assess the clinical features of the C9ORF72 expansion associated bvFTD (I). 
 
 
3. To analyse the frequency of the C9ORF72 expansion in early onset schizophrenia (II). 
 
 
4. To evaluate the presence of the C9ORF72 expansion in suicide victims (III). 
 
 
5. To clarify the role of the C9ORF72 expansion in the NHD phenotype (IV). 
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4 Materials and methods 
4.1 ETHICAL ASPECTS 
 
The ethics committee of Kuopio University Hospital approved the research protocols in 
studies I and IV. The ethics committee of the Northern Ostrobothnia Hospital District 
approved the research protocols in the studies I, II and III. Permission to gather data was 
obtained from the Ministry of Social and Health Affairs of Finland in study II. The permission 
for investigation of the suicide victims (study III) was granted by National Authority for 
Mediolegal Affairs of Finland. 
All the studies were conducted in accordance with the principles of the Declaration of 
Helsinki. Written informed consent was obtained from all the participants and/or their legal 
represent. In studies I-III, patients/victims’ records were anonymized and de-identified prior 
to analysis. 
This study was supported by grants from the Finnish Medical Foundation, the Finnish 
Alzheimer’s Research Foundation, the Finnish Brain Foundation, University of Eastern 
Finland, Orion Research Foundation and Finnish Cultural Foundation, North Savo Regional 
fund. The Funders had no role in the study design, data collection and analysis, decision to 
publish, or preparation of the manuscripts of the original publications or the thesis. The 
author confirms no conflicts of interest.  
The thesis was performed in Kuopio with data being collected from Kuopio and Oulu 
University Hospital Districts. 
 
4.2 STUDY POPULATIONS 
 
4.2.1 BvFTD cohorts (I) 
The patients of bvFTD cohorts in Oulu and Kuopio were collected from the outpatient clinics 
of Kuopio University Hospital and Oulu University Hospital from the years (1995-2014). A 
total of 43 patients was identified with the C9ORF72 expansion and FTLD clinical syndrome. 
Individuals with language variants were excluded (N=7) and thus the total cohort consisted 
of 36 patients with the phenotype of bvFTD.  Sixteen patients were males (44%). Four of the 
patients had bvFTD-ALS and 32 patients suffered from pure bvFTD. BvFTD had presented 
before ALS in three out of four cases. The characteristics of the study participants are shown 
in table 9. 
 
  
38 
 
 
Table 9. Characteristics of the study participants. 
 
 Years 
 Mean (SD) Range 95%CI 
Age at the onset of the symptoms 59.3 (6.6) 44-76 57.1-61.3 
Age at the diagnosis  61.2 (6.5) 46-79 59.1-63.4 
Duration of the symptoms until diagnosis 2.1 (1.7) 0-7 1.5-2.6 
Age at the death (N=18) 67.1 (6.5) 56-81 63.9-70.3 
Duration of the disease until death     
    Total cohort  6.7 (3.9) 1-13 4.8-8.7 
    Pure bvFTD without ALS (N=14) 7.8 (3.8) 1-13 5.6-10.0 
    bvFTD with ALS (N=4) 3.0 (0)   
Ages, standard deviations (SD), ranges and 95% confidence intervals of characteristics of the study 
participants (N=36). 
 
 
4.2.2 NFBC 1966 (II) 
The Northern Finland Birth Cohort 1966 (NFBC) consists of subjects who were born in the 
two most northern provinces of Finland (Oulu and Lapland) with expected birth in 1966. The 
total number of births was 12,231 (including 178 stillbirths) and their regional coverage was 
96.3% (http://www.oulu.fi/nfbc). The cohort has been followed since pregnancy and 
evaluated regularly by means of clinical examinations and health questionnaires.   
The present birth cohort study is based on 11,017 subjects. Eighty-three of them did not 
provide permission to access their data which meant that there were 10,934 participants. 
Information on diagnosis for psychoses was based on several sources including case note 
validation, register information and interviews (Keskinen et al. 2013). The validity of the 
diagnoses has been established and published (Moilanen et al. 2003). The subjects having a 
psychosis with an organic etiology were excluded. Thus, the present study population 
consisted of 94 subjects with schizophrenia spectrum disorder (45% women) and 36 subjects 
with other psychosis (56% women). Supporting data was collected from national registers, 
medical records and psychiatric examination at the age of 34- and 43-years. A blood sample 
was obtained to perform genetic analyses and screened for the presence and length of the 
C9ORF72 expansion. The characteristics of the study population are presented in table 10.  
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Table 10. Characteristics of the study subjects (N=130). 
Characteristics  
Females (n, %) 62 (48%) 
Education (n, %)1  
Basic 20 (15%) 
Secondary 100 (77%) 
Tertiary 10 (8%) 
Family history of psychosis (n, %) 32 (25%) 
Family history of any psychiatric disorders (parents or twins; n, %) 48 (37%) 
Diagnosis (n, %)  
Schizophrenia (DSM-codes; 295, 297.1) 94 (72%) 
Other psychoses (DSM-codes; 29604, 29624, 29634, 29644, 29654, 29664, 
2973, 2988, 2989) 
36 (28%) 
Age at onset of psychosis, years (mean, SD) 27.9 (7.0) 
1Level of education. Basic = under 10 years, secondary = 10-12 years and tertiary = over 12 years of 
education. 
 
4.2.3 Suicide cohort (III) 
The study sample consisted of 109 patients who had committed suicide in the province of 
Oulu, Northern Finland, between the years 1988-2004. The mean age at death by suicide was 
46 years (range 18-86, SD 17.0) and 31.2% (n=34) of suicide victims were 55 years old or older 
at the time of death. Clinical information of the suicide victims was collected from official 
death certificates, obtained from forensic medico-legal investigations. The life-time hospital 
admission diagnoses of the subjects were gathered from the Finnish Hospital Discharge 
Register collated by the National Institute of Health and Wellbeing. This nationwide register 
covers all inpatient hospital admissions in primary and specialized level care in Finland since 
the year 1969.  The characteristics of the study population are shown in table 11. 
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Table 11. Characteristics of the suicide victims (N=109). 
 
 
Characteristics  
 
Age at death, years (mean, SD, 95% Confidence interval) 46.1 (17.0, 42.9-49.63) 
Female gender (n, %) 15 (13.8%) 
History of psychiatric treatment, diagnosis (n, %)1  
Mental and behavioural disorders due to psychoactive substance use (F10-
19)                                        
23 (21.1%) 
Schizophrenia, schizotypal and delusional disorders (F20-29) 8 (7.3%) 
Mood (affective) disorders (F30-39) 28 (25.7%) 
Neurotic, stress-related and somatoform disorders (F40-48) 7 (6.4%) 
Behavioural syndromes associated with physiological disturbances and 
physical factors (F50-59) 
3 (2.8%) 
Disorders of adult personality and behaviour (F60-69) 8 (7.3%) 
Mental retardation (F70-79) 1 (0.9%) 
Disorders of psychological development (F80-89) None 
Behavioural and emotional disorders with onset usually occurring in 
childhood and adolescence (F90-98) 
None 
Violent method of suicide2 95 (87.2%) 
Method of suicide  
Hanging 36 (33.0%) 
Shooting 48(44.0 %) 
Gassing (carbon monoxide, butane etc.) 6 (5.5 %) 
Jumping from high place 4 (3.7 %) 
Poisoning 8 (7.3 %) 
Drowning 4 (3.7 %) 
Other 3 (2.8 %) 
Suicide done under the influence of alcohol 54 (49.5%)  
History of previous attempts of suicide  
None 90 (82.6%) 
Once 12 (11.0%) 
Twice or more 7 (6.4%) 
  
1According to International classification of diseases, version 10 (ICD-10). At least one inpatient treatment 
period in the following diagnosis; 2All methods except poisoning and gassing were classified as a violent 
method of suicide.  
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4.2.4 Siblings with Nasu-Hakola disease (IV) 
The first study examined three siblings with NHD. The genetic data was available on two 
out of three cases. The clinical data was available from official hospital charts as well as from 
forensic psychiatry records. One of the siblings carried the DAP12 mutation and one carried 
both the C9ORF72 expansion and the DAP12 mutation. All of the cases were male. The first 
of the siblings had not suffered any fractures but the others had fractured bones at the age of 
32 and 29 years. All of the cases revealed bone cysts in X-ray. The mean age at the personality 
change was 33 years (range 25-40) and the mean age at death was 42.8 years (range 37-48).   
 
 
4.3 CLINICAL AND IMAGING ASSESSMENT  
 
The clinical characterization of the patients was conducted by experienced physicians i.e. 
neurologists specializing in neurodegenerative diseases for the neurological assessment and 
an experienced psychiatrist undertook the psychiatric assessment. The demographical data 
of the patients was collected systematically from patient records and registers. A 
neuropsychological analysis was done during the normal diagnostic procedures.  
The assessment conducted in the memory outpatient clinics consisted different 
combination of  clinical and laboratory tests including CEDAD test battery, questionnaire of 
activities of daily living and mood symptoms, laboratory tests (ECG, blood count, glucose, 
potassium, sodium, calcium, thyroid tests, alanine aminotransferase, creatinine, B12-vitamin, 
albumin, serum proteins, glutamyl transferase, carbohydrate deficient transferrin), clinical 
(general and neurological) examination, structural neuroimaging (CT or MRI), CSF analyses 
(beta-amyloid, tau), neuropsychological assessment during diagnostic procedure, genetic 
analyses and PET/SPECT. 
Psychiatric symptoms were retrospectively assessed both prior to and at the phase of the 
diagnosis (I).  
Structural neuroimaging of the patients was undertaken by visual analysis of an 
experienced neuroradiologist. PET/SPECT scans were analysed systematically by visual 
analysis. 
 
4.4 GENETIC ANALYSES 
 
The C9ORF72 expansion (studies I-IV) was analysed in Kuopio by the repeat priming 
polymerase chain reaction assay (Renton et al. 2011). The sensitivity for that method has been 
estimated to be 94.3% and 97.3% for specificity (Akimoto et al. 2014). The length of the 
expansion was estimated by fluorescent fragment length analysis (ABI 3500x1 genetic 
analyser; Applied Biosystems Inc., Foster City, CA, USA). Previously confirmed pathological 
C9ORF72 expansion samples were used as positive controls and a specimen with a known 
four repeat expansion as a negative control. Borderline cases were confirmed by southern 
blot analysis (DeJesus-Hernandez et al. 2011) in Tampere University Hospital. Southern blot 
analysis has been regarded as a gold standard for detecting large polynucleotide repeat 
expansions (Akimoto et al. 2014).  
The homozygous deletion in DAP12 (Study IV) (Paloneva et al. 2000) was analysed by 
direct polymerase chain reaction assay with 1 forward primer (FP: 5′-
GGCCACATCCGTATGACTG-3′) and 2 reverse primers (RP1: 5′-TAGTATGTCCAG 
TCTCGAGTTCTCA-3′ and RP2: 5′-CTAGTCTGGGCGTGCATTC-3′). In the DAP12 deletion 
allele, the assay produces a 695-base pair (bp) amplicon (primers FP and RP2) and no product 
with primers FP and RP1. In the wild-type allele, the assay produces a 454-bp amplicon 
(primers FP and RP1) and no product with primers FP and RP2 (theoretical product size 5959 
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bp). The homozygous DAP12 deletion was detected in both of the siblings (cases II-2 and II-
3) providing a genetic confirmation to the diagnosis of NHD. 
Exome sequencing was performed in two out of three NHD cases using an Agilent 
HaloPlex Exome kit for target enrichment followed by sequencing on an Illumina MiSeq 
instrument to an average depth of 80× coverage. The resulting reads were mapped with 
Burrows-Wheeler Aligner (Li, Durbin 2009) after which the Genome Analysis Toolkit was 
used to identify variants (McKenna et al. 2010). The variants were annotated with 
ANNOVAR (Wang, Li & Hakonarson 2010).  
 
4.5 STATISTICAL METHODS 
 
All statistical test performed were two-tailed and a p value less than 0.05 was considered as 
statistically significant.  Analyses were done with SPSS 19. Survival assessment was 
performed with Kaplan-Meyer survival analysis. Sensitivities of the FTDC criteria were 
analysed statistically. 
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5 Results  
5.1 THE SENSITIVITY OF FTDC CRITERIA IN THE C9ORF72 EXPANSION 
CARRIERS (I) 
 
The total cohort of patients suffering from genetically defined bvFTD evaluated against the 
FTDC criteria. All those patients met the definite bvFTD criteria i.e. they were carrying a 
known pathogenic mutation (the C9ORF72 expansion) according to FTDC criteria. The 
sensitivities of these clinical criteria were evaluated in the total cohort, in the pure bvFTD 
cohort i.e. patients with no features of ALS and in a cohort of patients with bvFTD-ALS. These 
results are presented in table 12.  
 
Table 12. Sensitivities of FTDC clinical criteria in total cohort and subgroups. 
Characteristics Number of 
patients 
Sensitivity of 
criteria 
SD1 95%CI2 
Total cohort (N=36)     
Possible bvFTD3 27 0.75 0.44 0.57-0.87 
Probable bvFTD3 23 0.64 0.49 0.46-0.79 
bvFTD(N=32)4                                            
Possible bvFTD3 26 0.81 0.40 0.63-0.92 
Probable bvFTD3 22 0.69 0.47 0.50-0.83 
bvFTD-ALS (N=4)5     
Possible bvFTD3 4 0.25 N/A6 N/A6 
Probable bvFTD3 4 0.25 N/A6 N/A6 
1Standard deviation; 295% confidence interval; 3According to the FTDC criteria for bvFTD (Rascovsky et al. 
2011); 4Pure bvFTD without the features of early ALS; 5Combined clinical picture of early ALS and bvFTD; 
6Not available. 
 
The average number of behavioural and cognitive features required in the criteria of 
possible bvFTD in the total cohort was 3.19 (SD 1.26, 95%CI 2.77-3.62, range 1-6). Every case 
had at least one behavioural or cognitive feature determined as a bvFTD symptom from these 
criteria. The vast majority, 88.9%, of the patients had two or more symptoms and 75.0% 
exhibited three or more symptoms. Four or more features were encountered in 38.1% of the 
cases, five or more in 11.1% of the cases.  The total amount of all six cognitive and behavioural 
features was observed only in 5.6% of the cases. In pure bvFTD patients without ALS, the 
mean number of possible bvFTD features was 3.38 (SD 1.2, 95%CI 2.95-3.80, range 1-6), while 
in FTD-ALS patients, the number of possible bvFTD features was only 1.75 (range 1-3). All 
bvFTD-ALS cases demonstrated a positive neuropsychological profile for bvFTD, but most 
of the behavioral changes were not detected in clinical picture of these patients. 
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5.2 THE CLINICAL PHENOTYPE OF THE C9ORF72 EXPANSION CARRIERS 
ACCORDING TO FTDC CRITERIA (I) 
 
When the clinical features required for possible FTDC criteria were assessed, the 
neuropsychological profile revealed deficits in executive tasks combined with a relative 
sparing of both episodic memory and visuospatial skills in all the cases. Nonetheless, a 
neuropsychological analysis had been performed in only 32 of the total 36 cases during the 
early course of the disease.  
There were some relatively common behavioural findings (percentages in brackets) i.e. 
early behavioural disinhibition (66.7%) early apathy or inertia (61.1%) and early loss of 
empathy or sympathy (61.1%). Hyperorality and dietary changes were observed in 30.6% of 
the cases. A rather small number of the cases, a mere 8.3%, suffered from early loss of 
sympathy or empathy. These behavioural symptoms were retrospectively analyzed on all 
the cases.  
The mean age at death in the total cohort was 67.1 years (N=18, SD 6.5, 95%CI 6.39-70.3, 
range 56-81). The survival functions are displayed in figure 6.  
Figure 6. Kaplan-Meyer survival of the C9ORF72 expansion carriers. 
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5.3 NEUROIMAGING FINDINGS IN THE PATIENTS WITH THE C9ORF72 
EXPANSION ACCORDING TO FTDC CRITERIA (I) 
 
Neuroimaging (PET/SPECT and MRI or computed tomography, CT) alone displayed the 
highest sensitivity (0.86 sensitivity, SD 0.35, 95%CI 0.70-0.95) for recognition of bvFTD. MRI 
or CT criteria were fulfilled in 26 out of 36 cases (0.72 sensitivity) and PET/SPECT in 14 out 
of 17 cases (0.82 sensitivity). A diffuse cortical and central atrophy without a frontal or 
temporal predominance was detected in eight cases that did not fulfill the MRI criterion and 
the two remaining cases had normal findings in brain MRI imaging. A bilateral parietal 
hypoperfusion in PET scanning was identified in one case who did not fulfill PET criterion 
and the PET scan was assessed as normal in two of cases. 
The PET/SPECT was normal in 17.6% of the scanned individuals (three out of 17 patients) 
and thus they did not meet the PET/SPECT criteria for probable bvFTD. All these cases 
suffered from pure bvFTD without ALS. Their mean age at onset (53.7 years, SD 1.5, 95%CI 
49.9-57.5, range 52-55) and at their time of death (63.5 years, SD 2.1, 95%CI 44.4.-82.6, range 
62-65) they were significantly younger than the other patients. They displayed a mean 
number of 3.3 (SD 1.5 95%CI -0.46-7.13, range 2-5) possible bvFTD features and in addition, 
psychiatric symptoms were prevalent in all these cases. On the other hand, structural brain 
imaging provided evidence of bvFTD in all of these PET/SPECT negative cases. The mean 
duration of the disease from onset of symptoms to PET/SPECT scanning was 2.0 years in the 
PET/SPECT negative cases compared to a mean duration of 1.6 years in the PET/SPECT 
positive cases.  
When the neuroimaging results were combined with functional decline (possible FTDC 
criteria apart from behavioural features included in the probable bvFTD criteria), these 
figures achieved a slight enhancement in the sensitivity for the C9ORF72 expansion carriers 
i.e. 81% (N=29) of the patients were found to be positive with these criteria (0.81 sensitivity, 
SD 0.40, 95%CI 0.63-0.91). 
There were no signs of false positive cases in the MRI/CT or PET/SPECT results. A few of 
the cases that were initially interpreted as negative in PET/SPECT were corrected to positive 
in the second, more thorough, analysis. 
 
5.4 CLINICAL FEATURES OF THE C9ORF72 EXPANSION CARRIERS THAT 
DID NOT MEET THE FTDC CRITERIA (I) 
 
In all, 25% of the patients (N=9) did not meet the FTDC criteria for possible bvFTD. This 
subsection consisted of three patients with FTD-ALS and six with pure bvFTD.  Their mean 
age at the onset of symptoms was 56.6 years (SD 6.4, 95%CI 51.6-61.5, range 44-66) and 59.3 
years (SD 6.7, 95%CI 54.2-64.5, range 46-69) at the diagnosis. The corresponding values for 
the  patients meeting the criteria (N=27), were as follows – onset of symptoms 60.2 years (SD 
6.5, 95%CI 57.7-62.8, range 46-76) and diagnosis 61.9 years (SD 6.5, 95%CI 59.3-64.4, range 48-
79). Furthermore, the mean number of possible bvFTD features among the patients that did 
not meet the possible bvFTD criteria was 1.56 (SD 0.5, 95%CI 1.15-1.96, range 1-2). All of them 
exhibited disturbances in executive functions in the neuropsychological examination. 
Apathy or inertia was present in four of these subjects and one patient suffered from 
disinhibition, but none of the other possible bvFTD criteria were observed in any of these 
patients. However, 77.8% of these cases (N=7) did exhibit a positive neuroimaging result for 
FTLD and 66.7% of these cases (N=6) were positive in terms of both cognitive decline and 
neuroimaging.  
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5.5 PSYCHIATRIC SYMPTOMS IN THE PATIENTS WITH THE C9ORF72 
EXPANSION (I) 
 
The majority of the patients (61.1%; N=22) were found to be suffering from these symptoms. 
Psychotic symptoms without mood disturbances were detected in 30.6% (N=11) of the 
patients; 11.1% of the patients (N=4) displayed only mood symptoms, while 19.4% of the 
cases (N=7) experienced both psychotic and mood symptoms. The mean delay from the 
appearance of psychiatric symptoms to diagnosis of bvFTD was 4.6 years (95%CI 0.8-8.4, SD 
8.5). Although one patient had a 40 year history of a progressive atypical psychiatric disorder 
before diagnosis, the delay was less than ten years in the others.  Psychiatric symptoms were 
present in 55.6% (N=5) of the subgroup of patients that did not meet the FTDC possible 
criteria. 
 
 
5.6 THE C9ORF72 EXPANSION IN SCHIZOPHRENIA AND SUICIDES (II-
III) 
 
 
No pathological length C9ORF72 expansions as characterized by the typical descending saw-
tooth pattern (over 40 repeats) were detected in either of the two cohorts examined i.e. 
schizophrenia/psychosis patients or victims of suicide. In the schizophrenia/psychosis 
cohort, four samples were determined to have an intermediate amount of repeats (over 20 
repeats). For intermediate length expansion, see figure 7. In the same cohort, the mean 
number of the repeats was five, but there was great diversity in the range; from one to 30.  
 
 
 
Figure 7. Intermediate amount of the C9ORF72 repeats (22 repeats).  
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5.7 THE EFFECT OF THE C9ORF72 EXPANSION IN NASU-HAKOLA 
DISEASE (IV) 
 
One of the siblings was found to carry the pathological length C9ORF72 expansion. The 
homozygous DAP12 deletion was readily detected in the exome data of the analyzed NHD-
cases this being evidenced by the lack of any sequence reads in the DAP12 exons 1–4. All 
nonsynonymous variants in the presently known FTLD genes were screened (C9ORF72, 
CHMP2B, FUS, GRN, MAPT, TARDBP, VCP). Only one such variant was found in one out of 
the three cases, a MAPT*Y441H (NM_001123066:exon8:c.T1321C) heterozygote variant with 
a population frequency of 32% (1000 genomes), which was not predicted to be deleterious on 
the basis of PolyPhen2 and SIFT in silica tools (Adzhubei et al. 2010, Ng, Henikoff 2003). 
However, this same individual had also the heterozygous SOD1*D90A 
(NM_000454:exon4:c.A272C) mutation that, when homozygous, is known to cause a slowly 
progressive form of ALS (Andersen et al. 1995). In addition, a novel heterozygous mutation 
in the gene implicated in Lafora progressive myoclonic epilepsy type 2 (EPM2*A46P 
NM_001018041:exon1:c.G136C) was detected in this same individual (Serratosa et al. 1999). 
This variant was not found in either the 1000 genomes or in a Finnish population database of 
more than 5000 exomes (Sequencing Initiative Suomi, sisu.fimm.fi). The SOD1 and EPM2 
variants were confirmed by Sanger sequencing. 
All the patients displayed the typical features of NHD; bone cysts, personality changes, 
cognitive decline leading to severe frontal type dementia. In clinical terms, a slightly more 
severe picture of the disease was seen in the one of the patients without the C9ORF72 
expansion. The structural brain imaging revealed calcification in putamen and nucleus 
caudatus in all of the siblings but atrophy was also observed in nucleus caudatus, thalamus, 
frontal neocortic regions, frontal gyri, corpus callosum genu and parietal regions. No 
difference in the pattern of atrophy was detected between the C9ORF72 expansion carrier 
and non-carriers. 
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6 Discussion  
At the present time, no curative treatment is available for patients suffering from the 
C9ORF72 expansion associated diseases. Patients are often initially diagnosed as having 
some psychiatric disease even when the appropriate diagnosis is bvFTD. Even today, it is not 
known how many bvFTD patients remain undiagnosed in geriatric care institutions, forensic 
psychiatric institutions and psychiatric wards, especially during an era when postmortem 
neuropathological analyses are the exception rather than the rule (Ahlblad 2015).  
This is the largest study conducted to date (at least at the time when the reports were 
published) which has assessed the clinical picture of the C9ORF72 expansion associated 
bvFTD with and without ALS by applying the revised criteria for bvFTD (Rascovsky et al. 
2011) as well as being the first study to analyze the effect of this mutation in NHD. Due the 
intense research around the C9ORF72 expansion and FTLD, this thesis is particularly timely. 
The current set of studies provide essential information of the clinical phenotypes of patients 
with the C9ORF72 expansion. In addition, the prevalence of the mutation has not been 
analyzed previously in these types of cohorts.  
 
 
6.1 THE DISEASE COURSE IN THE C9ORF72 EXPANSION CARRIERS 
 
In the present study, the mean onset age was 59.3 years, which is in line with values in the 
literature. The onset of the bvFTD (all reported cases without genetic identification) has been 
estimated to occur typically between 50 and 60 years of age (Ratnavalli et al. 2002, Ikeda, 
Ishikawa & Tanabe 2004). Some reports have suggested that there might be an earlier onset 
of the disease for the C9ORF72 expansion associated bvFTD (Snowden et al. 2012, Devenney 
et al. 2014). Patients with the C9ORF72 expansion more often have a positive family history 
of early onset dementia or ALS (Snowden et al. 2012, Kaivorinne et al. 2013), and this may 
well aid the physician in making the correct diagnosis of these patients. Furthermore, the 
prominent behavioural features (Snowden et al. 2012), psychosis (Snowden et al. 2012, Sha et 
al. 2012, Devenney et al. 2014) and executive task deficits (Snowden et al. 2012) may lead to 
an earlier detection of bvFTD. However, the onset of bvFTD in the patients examined here 
was not evidently earlier although it has to be stated that there was extensive variability in 
the onset ages (from 44 to 76 years), which is in line with other reports of C9ORF72 expansion 
carriers (Snowden et al. 2012, Devenney et al. 2014).  
The mean age at the death of patients was 67.1 years in the present study. The duration 
from onset to death was observed to be 6.7 years in the total cohort (bvFTD and bvFTD+ALS), 
with the survival being slightly prolonged in the subgroup of patients with pure bvFTD (7.8 
years); in contrast it was much shorter, only 3.0 years, in the group of patients with bvFTD-
ALS. In previous studies, the mean survival in FTLD from onset to death has been estimated 
as eight years (Neary, Snowden & Mann 2005).   
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6.2 THE PHENOTYPE OF THE C9ORF72 EXPANSION CARRIERS 
 
The validity of the FTDC criteria were investigated among the bvFTD and bvFTD-ALS 
patients with the C9ORF72 expansion diagnosed in the neurology outpatient clinic. The 
sensitivities in the total cohort were rather high, 75%, for possible bvFTD and 64% for 
probable bvFTD. After the patients with bvFTD-ALS were excluded then these sensitivity 
figures increased i.e. 81% for possible and 69% for probable bvFTD, these values being 
significantly higher than those previously reported (60% and 38% respectively) for the 
C9ORF72 expansion carriers (Devenney et al. 2014).  In cases with neuropathologically 
confirmed definite bvFTD (in whom there was no knowledge of the genetic basis of the 
disease), the sensitivities were the highest i.e., 86%-95% for possible bvFTD and 75%-85% for 
probable bvFTD (Rascovsky et al. 2011, Harris et al. 2013). In summary, it seems that FTDC 
criteria identify a significant proportion of bvFTD patients with the C9ORF72 expansion at 
the time of examination in the neurological outpatient clinic. 
The main features of bvFTD according to recent FTDC criteria (Rascovsky et al. 2011), are 
disinhibition, apathy or inertia, loss of sympathy or empathy, perseverative, stereotyped or 
compulsive/ritualistic behaviour, hyperorality and dietary changes and executive deficits. In 
the C9ORF72 expansion associated bvFTD, apathy and inertia, disinhibition and 
repetitive/stereotyped behaviour have been observed very frequently (Snowden et al. 2012, 
Devenney et al. 2014). These three features; disinhibition, apathy/inertia and 
repetitive/stereotyped are also the principal symptoms encountered in the present study, 
representing the “core” behavioural signs of the C9ORF72 expansion associated bvFTD. In 
contrast, hyperorality and dietary changes were observed relatively rarely in the C9ORF72 
expansion associated disease (Snowden et al. 2012). Similarly there were a rather low number 
(one out of every three) of hyperorality and dietary changes detected in the carriers of the 
C9ORF72 expansion.  In the present study, the lowest sensitivity was found for early loss of 
sympathy or empathy (8.3%). This trend was reported also in the neuropathologically 
confirmed but genetically unconfirmed cohorts from UK and Australia (Chare et al. 2014).  
In general, the core distinctive symptom in bvFTD seems to be disinhibition of behaviour 
(Barber, Snowden & Craufurd 1995, Levy et al. 1996, Hirono et al. 1999, Bozeat et al. 2000, 
Bathgate et al. 2001, Srikanth, Nagaraja & Ratnavalli 2005, Blair et al. 2007, Heidler-Gary et 
al. 2007, Liscic et al. 2007, Rankin et al. 2008). However, the most common and prominent 
symptom in bvFTD is apathy and/or inertia (Diehl-Schmid et al. 2006, Le Ber et al. 2006, 
Mendez et al. 2008a).  Initially, hyperorality was considered to be the rarest behavioural 
symptom, although it has been subsequently detected in approximately 55% of the cases 
(Rascovsky et al. 2011).  
It is possible that cultural factors may influence the detection of behavioural symptoms of 
bvFTD patients. A recent study suggested that in eastern Mediterranean culture bvFTD 
symptoms may not be considered as a medical issue, instead, these symptoms can be viewed 
as normal ageing (Papatriantafyllou et al. 2009). Similarly, in Finnish patient records, the 
presence/loss of empathy or sympathy was not often mentioned and it may be that the 
expression of emotions in Finnish culture is not considered appropriate and is probably less 
common than in English-speaking cultures; one could argue convincingly that the failure to 
express emotions may be thought of as normal behaviour in Finland.  
Initially, the neuropsychological profile was found to be consistent with bvFTD in only 
approximately 60% of the cases (Rascovsky et al. 2011). However, in the C9ORF72 expansion 
associated disease, the cognitive profile was found to be consistent with bvFTD in almost all 
of the subjects (Snowden et al. 2012). These results consolidate this impression as there was 
very high sensitivity detected for neuropsychological assessment in the C9ORF72 expansion 
carriers (i.e. all the cases fulfilled these criteria).  Hence, the neuropsychological assessment 
seems to be a major distinguishing feature in differentiating between the cohorts of the 
C9ORF72 expansion carriers and non-carriers. 
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Initially, the imaging for the FTDC criteria (without distinguishing functional or 
structural method of imaging) for bvFTD were found to have approximately 80% sensitivity 
(Rascovsky et al. 2011). Subsequently, in the C9ORF72 expansion carriers, the sensitivity was 
found to be 61% for structural and 94% for functional imaging (Snowden et al. 2012).  
Snowden and colleagues did not detect any difference in neuroimaging findings between the 
expansion carriers and non-carriers. In another study, the C9ORF72 expansion carriers 
presented more parietal and bilateral thalamic atrophy than non-carriers, whereas non-
carriers with bvFTD displayed more medial frontal atrophy (Sha et al. 2012).  
In the present study, results are more in line with the results of Snowden and colleagues; 
values of 72% for sensitivity with MRI/CT and 82% for sensitivity with PET/SPECT. 
However, this sensitivity for PET/SPECT scan is surprisingly low because the scan was taken 
after the disease had been clinically present only for a mean of three years. When PET/SPECT 
scans and structural brain imaging findings were combined for detecting bvFTD, the 
sensitivity reached 86%. This underlines the fact that the C9ORF72 expansion associated 
bvFTD may lead to the emergence of devastating clinical symptoms, consistent with those 
listed in the bvFTD diagnostic criteria, but with no detectable hypoperfusion or brain atrophy 
in neuroimaging. However, the clinical benefit of the neuroimaging may even be slightly 
lower as the specificity of the neuroimaging was not assessed. This issue needs to be noted 
in clinical work in memory clinics, but also psychiatrists need to consider a somatic reason 
for psychiatric symptoms; it is not possible to exclude a somatic reason simply by 
neuroimaging of the patient. The reason for occasional lack of atrophy or hypoperfusion in 
the C9ORF72 expansion associated bvFTD has remained unknown. Nonetheless, there are 
no validated radiological assessment scales for evaluating frontotemporal atrophy, and this 
is very different from the situation in AD where there are clearly defined terms to be applied 
in any assessment of the hippocampal atrophy. Furthermore technical limitations in the 
current neuroradiological methods may be a reason for not detecting signs of atrophy. In 
addition, it would be very useful to conduct a post-mortem analysis of those cases in which 
there were no neuroradiological signs of atrophy.  
 
 
6.3 PSYCHIATRIC SYMPTOMS IN THE C9ORF72 EXPANSION CARRIERS 
 
Psychiatric symptoms were rather prominently displayed in the early course of the C9ORF72 
expansion associated bvFTD. A total of 61 % of the patients were suffering from psychotic, 
mood or both psychotic and mood symptoms. 
Psychotic symptoms have been claimed to be very rare among the patients with bvFTD 
(Bathgate et al. 2001, Mendez et al. 2008a, Mendez et al. 2008b) and it has been estimated that 
the prevalence of delusions would be 2.3% with hallucinations being absolutely totally absent 
(Mendez et al. 2008b). In 2011, Snowden and colleagues (2012) detected a strong association 
between psychotic symptoms with the C9ORF72 expansion. They estimated that the odds of 
having the expansion would be 15-fold higher if the patient displayed features of psychosis. 
Interestingly, psychosis has not been reported in patients carrying MAPT (Hutton et al. 1998) 
or progranulin (PGRN) (Baker et al. 2006) mutations.  Nonetheless, cases with FUS pathology 
have reported to have an elevated incidence of psychotic symptoms (Seelaar et al. 2010, 
Urwin et al. 2010, Snowden et al. 2011). Therefore, Snowden and colleagues hypothesized 
that psychotic symptoms would be encountered only in those cases that are attributable to 
the factors that can cause also ALS (FUS pathology and the C9ORF72 expansion), since MAPT 
and PGRN are not associated with ALS (Snowden et al. 2012). In other words, one could 
argue that the familial bvFTD cases with psychotic symptoms would be caused by the 
C9ORF72 expansion, since the FUS pathology is much rarer and tends to be present in 
sporadic cases.  
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At present, three studies have analysed the types of psychotic symptoms found in the 
C9ORF72 expansion carriers. The first publication did not determine the number of psychotic 
symptoms, instead it focussed on the extensive delusions as a presenting symptom of bvFTD 
(Sha et al. 2012). In two other studies, psychotic symptoms were present in 35-40% of cases 
(Devenney et al. 2014, Snowden et al. 2012). No difference was detected in functional or 
structural neuroimaging between patients with psychotic and non-psychotic symptoms of 
the disease (Snowden et al. 2012). In the present study, the number of psychotic symptoms 
was even higher than previously reported i.e. 50% of the patients had been reported by a 
psychiatrist to have psychotic symptoms and 31% to have mood symptoms and in fact about 
one in every five (19%) had both psychotic and mood symptoms. The mood symptoms 
consisted mainly of depressive episodes but a few manic conditions were detected. There are 
no previous studies published analysing or indicating major depressive symptoms in the 
C9ORF72 expansion carriers. Patients with the C9ORF72 expansion associated bvFTD show 
a remarkable amount of apathy or inertia in the early course of the disease. Therefore apathy 
or inertia may be interpreted as symptoms of depression. 
In the present study, psychiatric symptoms were observed either during the diagnostic 
process or before the initial suspicion of bvFTD. The estimated figures for psychiatric 
(mis-)diagnoses may reflect the confusion of clinicians when they are examining these 
patients, i.e. very often the patients have been subjected to both neurological and psychiatric 
diagnostic batteries. Nonetheless, the diagnostic process seems to be adequate, as the present 
patients received the correct diagnosis quite rapidly after the initial symptoms, at least as 
soon as reported in some other studies (Rosso et al. 2003, Nunnemann et al. 2011, Hodges et 
al. 2003).  
One other interesting claim has been that the C9ORF72 expansion seems to predict 
psychiatric illnesses and symptoms in family members of the carriers (Devenney et al. 2014), 
which may indicate that a lower expansion copy number may cause milder neuropsychiatric 
syndromes than in the full-blown bvFTD. This hypothesis is supported by the finding that 
the C9ORF72 expansion seems to anticipate the onset of symptoms in successive generations 
within a pedigree (Benussi et al. 2014).   
 
 
 
6.4 THE ROLE OF THE PATHOGENIC C9ORF72 EXPANSION IN 
PSYCHIATRIC CONDITIONS 
 
The C9ORF72 expansion associated bvFTD seems to cause an exceptionally large number of 
psychotic symptoms (Snowden et al. 2012, Devenney et al. 2014). On the other hand, 
schizophrenia and other psychoses are associated with structural brain abnormalities, but it 
is controversial whether these are static or progress over time   (Tanskanen et al. 2010). There 
is convincing evidence that patients with schizophrenia suffer from cognitive impairments 
(Murray et al. 2006, Rajji, Ismail & Mulsant 2009). The most pronounced deficit areas are 
found in attention, executive functions and memory, which are the same deficit areas as 
encountered in patients with FTLD. In spite of these connections, there was no evidence of 
the pathological length C9ORF72 expansion in the members of Northern Finland Birth 
Cohort 1966 in patients diagnosed with early onset schizophrenia or other psychoses. This 
indicates that the pathological length C9ORF72 expansion does not play a major role in early 
onset schizophrenia or in other early onset psychoses. These findings support the concept 
that the onset of the C9ORF72 expansion associated psychiatric phenotypes occur mainly in 
middle age or even later.  However, even although no expansions with over 40 repeats were 
found, there were a few intermediate length repeat expansions. The role of intermediate 
expansion will be discussed in chapter 6.6.  
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Suicide is typically a long process with a multimodal etiology. Pathological 
neurobiological factors, certain genetic abnormalities and in particular, psychosocial factors 
are known to raise the risk for suicidal behaviour and suicide (Furczyk et al. 2013, Statham 
et al. 1998, Pandey 2013, Hawton, van Heeringen 2009). In particular, mutations affecting the 
proteins in the serotonergic pathway are known to elevate the risk of suicide. For example, 
polymorphism of the tryptophan hydroxylase 1 gene is a quantitative risk factor for suicidal 
behaviour and the polymorphism of serotonin transporter gene has been found to elevate 
the risk for violent method and repeated suicide attempts (Bondy, Buettner & Zill 2006). It is 
clear that the genetic architecture behind a suicide attempt may be rather polygenic but 
unfortunately GWAS studies have not found any clear genetic risk factor combinations in the 
polygenic score studies (Mullins et al. 2014). Impulsivity is a known risk factor for suicide 
(Mann 2003, Hawton, van Heeringen 2009) and malfunction of the prefrontal cortex has been 
associated with impulsivity which increases the suicide risk (Mann 2003).   
Suicide is observed more than would be expected in the patients with dementia and 
usually these patients also have a higher risk for suicide ideation (Erlangsen, Zarit & Conwell 
2008, Purandare et al. 2009). The suicidal behaviour and suicide attempts seem to be higher 
in non-Alzheimer dementia (Peisah et al. 2007). The frontal type dementia has been most 
commonly related to suicide (Alberici et al. 2012) and suicide attempts have been seen also 
in patients with semantic dementia (Hsiao et al. 2013). It has been speculated that the risk for 
suicide in the dementia patients is highest in patients suffering from bvFTD (Erlangsen, Zarit 
& Conwell 2008). This hypothesis is supported by the fact that bvFTD is characterized by 
personality changes, social dysfunction, apathy, impairments in the functions governed by 
frontal brain areas and a substantial  amount of neuropsychiatric symptoms, including 
impulsivity (Rascovsky et al. 2011). Self-injurious behaviour has been described in bvFTD 
(Mendez, Bagert & Edwards-Lee 1997). Impulsive behaviour, rash or careless activities when 
combined with psychiatric symptoms may be present several years before there are any 
cognitive changes or features of dementia (Rascovsky et al. 2007). Interestingly, the suicide 
risk in patients with dementia seems to be highest at the time of initial diagnosis (Erlangsen, 
Zarit & Conwell 2008). There are other factors which if present are known to elevate the risk 
for suicide in dementia patients i.e. depression, young age and retained insight (Haw, 
Harwood & Hawton 2009, Lim et al. 2005, Purandare et al. 2009, Seyfried et al. 2011). 
However, there are very few studies which have examined suicide and suicidal behaviour in 
patients suffering from dementing diseases and even in these reports, the sample sizes have 
been limited (Haw, Harwood & Hawton 2009).  
A suicide attempt has been reported to be a potential initial symptom of bvFTD (Fonseca 
et al. 2014). In addition, a suicide attempt has reported as being the first sign of bvFTD in one 
case with the C9ORF72 expansion (Synofzik et al. 2012). While the risk of suicide seems to be 
increased among the patients with bvFTD (Erlangsen, Zarit & Conwell 2008) on the other 
hand, suicidality has been suggested to have over 40% heritability (Statham et al. 1998, 
Furczyk et al. 2013, Pandey 2013). Therefore it seemed reasonable to analyse the C9ORF72 
expansion in postmortem blood samples of victims of suicide. Although there is a high 
prevalence of the C9ORF72 expansion associated bvFTD in Finland (Majounie et al. 2012b, 
Renton et al. 2011) in the present cohort of suicides, it was not possible to detect any 
pathological length expansions. This indicates that a suicide in a patient with the C9ORF72 
expansion associated bvFTD would simply be a coincidence rather than a typical symptom. 
However, there are no other studies which have examined the prevalence of the C9ORF72 
expansion in suicide victims and thus other trials with larger sample sizes will be needed to 
confirm this finding. 
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6.5 THE ROLE OF THE C9ORF72 EXPANSION LENGTH 
 
The intermediate length C9ORF72 expansion was observed in 3% of early onset 
schizophrenia/ early onset psychosis patients. The exact repeat length size for pathogenic 
mutation is not known. It has become a convention to state that there should be a length of 
30 repeats or more for it to be interpreted as being positive for the C9ORF72 expansion 
(Renton et al. 2011).  On the other hand, repeats as high as 60-65 have been considered as a 
lower limit of pathological expansion repeat numbers (Loy et al. 2014, Gijselinck et al. 2012). 
The normal physiological amount of repeats is thought to range from 2 to 24 repeats, whereas 
repeat numbers from 7 to 24 have been interpreted as being potential risk alleles; this is called 
an intermediate length expansion (van der Zee et al. 2013). At present, there is no data about 
the frequency of the intermediate length C9ORF72 repeat expansions in the Finnish healthy 
population. 
A correlation has been found between the number of repeats and an earlier onset age of 
FTLD (Benussi et al. 2014). There is an earlier appearance of the disease in successive 
generations within a pedigree i.e. the mean difference in onset age between parent and child 
was 9.8 years. Recently, there have appeared a few published studies that intermediate 
expansions would be seen more in familial and sporadic FTLD than in healthy controls (van 
der Zee et al. 2013, Xi et al. 2012) and the intermediate length C9ORF72 expansions may cause 
a later onset of the disease and milder disease. The same kind of earlier appearance (so-called 
anticipation) associated with repeat expansion mutation has been observed also in some 
other neurodegenerative diseases e.g. in HD, where onset age is earlier in those patients with 
a higher number of repeats (Wexler et al. 2004). In general, these recent findings emphasize 
the fact that the threshold between normal and pathological expansion should be lowered to 
even as low as seven repeats.  
Some authors have suggested that the intermediate length C9ORF72 expansion would 
possess some disease modifying significance. A study of 127 Chinese patients suffering from 
spinocerebellar ataxia type 3/ Machado-Joseph disease revealed that those patients having 7-
30 repeats had an earlier onset of the disease, i.e. by nearly three years, compared to non-
carriers (Wang et al. 2015). Another study claimed that repeats from 20 to 30 in length would 
be a risk factor for PD (Nuytemans et al. 2013). Finally, one Italian group postulated that it 
was the intermediate repeats (20-30) that would be either modifying PD into a non-classical 
atypical form of PD without dementia or to change the disease so that it was typical PD 
complicated with psychosis (Cannas et al. 2015). The role of these intermediate repeats in 
different diseases is still unknown and especially their role in psychiatric diseases and other 
slowly progressive and atypical neurodegenerative syndromes should be evaluated. It has 
also been claimed recently that instead of the length of the mutation, it is epigenetical factors 
that may be responsible for the pathogenesis of the C9ORF72 repeat expansion (Gijselinck et 
al. 2015). 
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6.6 THE EFFECT OF THE C9ORF72 EXPANSION IN NASU-HAKOLA 
DISEASE PHENOTYPE  
NHD is a rare neurodegenerative disease leading to frontal dementia at a very young age.  
(Hakola 1990, Hakola, Iivanainen 1973, Paloneva et al. 2001). NHD is caused by TREM2 or 
DAP12 mutations. Both of those genes have important functions in myeloid lineage cells and 
therefore it has been postulated that the mechanism behind the NHD would be attributable 
to disturbances in the function of osteoclasts and microglial cells. However, one research 
group indicated that DAP12/TREM2 function might not be responsible for development of 
the neuropathological manifestation of NHD (Satoh et al. 2011). Disturbances in calcium 
homeostasis have also been suggested to be one component of the pathogenesis of NHD 
(Satoh et al. 2011) but no elevated calcium levels have reported in the patients with NHD. 
These findings emphasize the necessity of identifying other mechanisms to explain rapid 
neurodegeneration in the NHD affected brain.  
The present study evaluated three deceased siblings known to possess a mutation in 
DAP12. A DNA sample was available in two cases and also the C9ORF72 expansion was 
identified in one of those two samples. The onset of the NHD is about 10-30 years earlier than 
is the case with the C9ORF72 expansion associated bvFTD (Majounie et al. 2012b). It is known 
that in general the neurodegeneration and neuropathological changes may appear even 
decades before the clinical symptoms of dementing disease (Jack et al. 2010). Therefore, since 
the C9ORF72 expansion was detected in one patient with the NHD, it was tempting to 
speculate that the C9ORF72 expansion would impact on the NHD phenotype and lead to a 
more progressive phenotype. However, it was not possible to detect any differences in the 
clinical signs, onset ages or disease progression in the C9ORF72 expansion carrier versus the 
non-carrier. Furthermore, the imaging findings were similar in both subjects.  
 
 
6.7 STRENGTHS AND LIMITATIONS 
 
The present cohort of C9ORF72 expansion carriers is extensive and all of the patients have 
been carefully examined by a neurologist specializing in dementing diseases. Furthermore, 
a large number of functional brain imaging scans were performed. The study performed in 
patients with early onset schizophrenia and other psychoses was extremely well designed 
from a clinical point of view as these patients have been part of a birth cohort study and thus 
the data is accurate and well validated. Since there was a strong consistent result, it means 
that these results can be generalized to represent early onset schizophrenia. In contrary, our 
study cannot be generalized to late onset schizophrenia or psychosis.   
In Finland, forensic autopsies are performed routinely in violent deaths which made it 
possible characterize reliably the prevalence of the C9ORF72 expansion among suicide 
victims. In addition, both younger and older subjects could be included into that study. This 
study’s accuracy is also increased because of the genetic isolation of the Finnish people and 
the high prevalence of the C9ORF72 expansion in Finland. Hence the validity of research is 
rather high. 
The validity of our genetic analysis of the C9ORF72 expansion was confirmed by analyzing 
both positive and negative controls. The numbers of expansions were also counted among 
the positive and intermediate cases, thus these present results may be considered as reliable 
and accurate.  
Even though the cohorts are quite large in comparison with previously published reports, 
the main limitation of this study is the limited number of patients in each cohort. The minor 
limitations include the fact that no neuropathological data were assessed (due the low 
number of samples) in the present set of studies.  
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6.8 CLINICAL IMPLICATIONS 
 
Based on the present findings, the FTDC criteria (Rascovsky et al. 2011) may be used for 
screening for the C9ORF72 associated bvFTD. The most significant symptoms which should 
lead to a suspicion of bvFTD, are apathy or inertia, disinhibition and loss of manners and 
repetitive/stereotyped behaviour. These symptoms should be systematically screened in 
clinical practice, for example by subjecting the subject to the frontal behavioral inventory 
(FBI) query (Kertesz et al. 2000, Kertesz, Davidson & Fox 1997). The appearance of deficits in 
executive tasks, while visuospatial skills and episodic memory remain undisturbed, should 
reinforce this suspicion.   One cannot dismiss the possibility that it is a somatic disease, 
especially bvFTD, behind the psychiatric symptoms simply by performing structural brain 
imaging or PET/SPECT as the sensitivities of these approaches are rather low for the 
C9ORF72 associated bvFTD. The exclusion of neurological etiology should be done by a 
neurologist specializing in dementing diseases, especially in neuropsychiatric diseases. 
When there is a clear suspicion of bvFTD, genetic tests to identify the C9ORF72 expansion 
should be conducted as some of the carriers may present with only a limited number of 
neuropsychiatric symptoms and may have rather minor or even non-detectable in changes 
in neuroimaging.  
In addition, middle-age or later life onset of severe psychiatric disease should be 
considered as a possibility of bvFTD. In particular, patients with no clear environmental 
etiological factors, with features of ALS or parkinsonism,  with a poor or even untoward 
response to antipsychotic medication (e.g. the development of extrapyramidal side effects), 
with a progressive deterioration of ADL-functions and with first or second degree relative 
with dementia or ALS should be screened for the C9ORF72 expansion.  However, suicidal 
behavior in general or schizophrenia before middle age should not be considered as a 
C9ORF72 expansion associated disease. 
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7 Conclusions 
Based on the findings of the present set of studies, the following conclusions can be drawn: 
1. The revised criteria for bvFTD (Rascovsky et al. 2011) recognize a substantial amount 
of the C9ORF72 expansion carriers (I).  
2. The C9ORF72 expansion carriers display a remarkable number of psychotic and mood 
symptoms. The diversity of the clinical phenotypes is extremely broad (I). 
3. Functional and structural brain imagings do not detect all of the patients with the 
C9ORF72 expansion. Thus neuroimaging on its own is not sufficiently sensitive and 
cannot solely be used as exclusionary method in ruling out a somatic etiology behind 
the psychiatric symptoms (I). 
4. Despite the high frequency of psychiatric symptoms in bvFTD patients, the 
development of schizophrenia before the age of 43 is not associated with the full length 
pathogenic C9ORF72 expansion (II). 
5. The C9ORF72 expansion is not associated with suicide. A suicide attempt in a carrier 
of the C9ORF72 expansion should be considered as a coincidence rather than a cause 
and effect relationship (III).  
6. The presence of the C9ORF72 expansion does not influence the phenotype or disease 
course in NHD (IV). 
 
58 
 
 
 
  
59 
 
 
8 Future perspectives 
At the present time, neurodegeneration is the subject of the very intense and ground-
breaking research. The mechanisms involved in both the genetic and environmental factors 
are still largely unknown for these diseases. The finding of the C9ORF72 expansion has 
helped to clarify the situation in FTLD and ALS but the role of this expansion in milder 
neurodegenerative diseases has remained far from clear. In addition, it is not understood 
why the same mutation should cause such very different clinical phenotypes. Assessing the 
clinical phenotypes of the C9ORF72 expansion is a very important issue, it is hoped that we 
will soon see the discovery and clinical approval of disease modifying drugs, based on the 
mutation (especially highly specific drugs and gene therapy). 
In the future, other phenotypes of the C9ORF72 carriers and also other clinical conditions 
which may be associated with the mutation may well be revealed. There is very limited data 
about the C9ORF72 expansion associated language variant of FTLD and the clinical and 
neuroradiological profile should be characterized. However, the PPA phenotype is rare and 
if one wishes to examine large cohorts then one will need international collaboration. 
Another aspect worth consideration is the phenomenon that bvFTD is associated with 
psychotic behaviour, disinhibition and lack of emotionality. In addition, recent studies have 
reported criminal behaviour and rather high numbers of crimes committed by patients with 
bvFTD. Thus, as a short term continuum for this project, screening patients in forensic 
psychiatric facilities, prisons and geriatric/psychogeriatric facilities could provide essential 
information to reveal the true clinical spectrum of bvFTD. If undiagnosed bvFTD patients are 
held in facilities such as prisons or forensic psychiatric institutions, this knowledge may have 
legal implications and thus change those individuals’ lives as well as being of considerable 
scientific interest. Hence, that kind of research topic could be deemed as both highly ethical 
and necessary. In addition, the connections between the C9ORF72 expansion and conditions 
like treatment resistant depression, social marginalization, ADHD, and atypical alcoholism 
should be analysed.  
Many studies have reported that the prevalence of the C9ORF72 expansion in Finland is 
one of the highest in the world. However, there is no data about the prevalence of the 
C9ORF72 expansion or intermediate length expansion repeats in the Finnish population. One 
way to analyse the prevalence of the mutation and its intermediate forms in Finnish 
population would be to utilize Finnish biobanks, Finnish Red Cross blood samples or/and, 
birth-cohort samples. The knowledge emerging from that kind of study would also help to 
clarify the essential characteristics of undiagnosed individuals with the pathological 
mutation as well as the role of the intermediate length of the expansion. 
Even though the C9ORF72 expansion is gradually becoming better understood, there is 
still no explanation for the enormous diversity within the phenotype – in fact it is very 
difficult to pin down the so-called core phenotype. Factors that contribute to the phenotypic 
diversity have not been described in the literature. Thus, for example, it could be predicted 
that GWAS analyses in patients carrying the C9ORF72 expansion may reveal the genetic 
factors that lead to a certain clinical subtype of the C9ORF72 associated disease.  
Until recently, dementia used to be considered to be a psychiatric syndrome. In fact, not 
so long ago neurology and psychiatry were part of the same speciality. Subsequently these 
specialities have divided and drifted surprisingly far away from each other. In fact, the 
development of neurology may be viewed as having emerged from the identification of 
neurobiological factors which evoke the observed behavioural and cognitive syndromes.  In 
particular, bvFTD has only rather recently been understood as being a neurobiological 
disease. Today our understanding of the reason why certain biological factors are responsible 
for the behavioural and cognitive disturbances is increasing rapidly, and therefore it would 
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now seem to be a suitable time to conduct ground-breaking research at the interface between 
these two specialities; exploring the neurological factors behind the psychiatric conditions by 
combining neuroimaging, genetics, neuroimmunological techniques as well as performing 
inflammatory factor analyses and exploiting other neurobiological approaches.  
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Behavioural variant frontotemporal 
dementia (bvFTD) is a less well-known 
neurodegenerative disease. The C9ORF72 
expansion is the most common genetic 
etiology for bvFTD in Finland. There is a 
broad phenotype in the C9ORF72 expansion 
associated bvFTD; psychiatric symptoms 
are pronounced. This thesis focuses on 
characterizing the clinical phenotype and 
diagnostics of the C9ORF72 expansion carriers; 
this will be an important issue when new 
targeted pharmaceuticals become available.
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